Original Article
Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
N Engl J Med 2004; 351:2049-2057November 11, 2004
- Abstract
Background
We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy.
Methods
A total of 1050 black patients who had New York Heart Association class III or IV heart failure with dilated ventricles were randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addition to standard therapy for heart failure. The primary end point was a composite score made up of weighted values for death from any cause, a first hospitalization for heart failure, and change in the quality of life.
Results
The study was terminated early owing to a significantly higher mortality rate in the placebo group than in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs. 6.2 percent, P=0.02). The mean primary composite score was significantly better in the group given isosorbide dinitrate plus hydralazine than in the placebo group (–0.1±1.9 vs. –0.5±2.0, P=0.01; range of possible values, –6 to +2), as were its individual components (43 percent reduction in the rate of death from any cause [hazard ratio, 0.57; P=0.01] 33 percent relative reduction in the rate of first hospitalization for heart failure [16.4 percent vs. 22.4 percent, P=0.001], and an improvement in the quality of life [change in score, –5.6±20.6 vs. –2.7±21.2, with lower scores indicating better quality of life; P=0.02; range of possible values, 0 to 105]).
Conclusions
The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure including neurohormonal blockers is efficacious and increases survival among black patients with advanced heart failure.
Media in This Article
Figure 1
Kaplan–Meier Estimates of Overall Survival.Table 1
Scoring System for the Primary Composite End Point.Article Activity
- Article
Neurohormonal inhibitors alone or in combination slow the progression of left ventricular dysfunction, retarding the structural remodeling of the left ventricle that characterizes chronic heart failure and reducing the rates of death and complications among patients with heart failure.1-10 Endothelial dysfunction, impaired bioavailability of nitric oxide, and increased oxidant stress also occur in patients with congestive heart failure and contribute to the remodeling process in experimental and clinical models of heart failure.11-27 Augmentation of nitric oxide may therefore be an alternative or supplemental approach to slow or reverse progressive heart failure. The first Vasodilator Heart Failure Trial (V-HeFT I)6 demonstrated the benefit of combining the nitric oxide donor isosorbide dinitrate with the antioxidant hydralazine in patients with mild-to-severe heart failure; however, the potential long-term benefit of this therapy in patients treated with neurohormonal inhibitors has not been evaluated.
Differences exist in the prevalence and causation of congestive heart failure and in the associated morbidity and mortality, consistent with population-based variations in the mechanisms of heart failure.28-30 Studies have suggested that persons who identify themselves as black may have, on average, a less active renin–angiotensin system29,31 and a lower bioavailability of nitric oxide than those self-identified as white.32-37 Retrospective analyses of the databases of previous heart-failure trials38,39 strongly suggested that black patients have a clinically significant response to a combination of isosorbide dinitrate and hydralazine. On the basis of these observations, we evaluated the efficacy of a fixed dose of isosorbide dinitrate plus hydralazine in black patients who had New York Heart Association (NYHA) class III or IV heart failure with dilated ventricles and who were receiving background therapy that included neurohormonal blockers.
Methods
Study Design
The African-American Heart Failure Trial (A-HeFT) was a randomized, placebo-controlled, double-blind trial with patients recruited at 161 centers in the United States. The study protocol was reviewed and approved by the institutional review board at each site. All patients gave written informed consent. Site monitoring, data collection, and data management were performed by Medifacts International, a clinical research organization. Data analysis was performed by independent statisticians and by Virtu Stat. The study sponsor was NitroMed. Independent committees adjudicated all primary and secondary end points, reviewed data on safety, and oversaw the two prespecified interim analyses, which were performed solely to assess the adequacy of the sample size. The manuscript was prepared by the authors and reviewed by the steering committee and the sponsor. The study design has been described previously.40,41
Inclusion and Exclusion Criteria
Patients 18 years of age or older, self-identified as black (defined as of African descent), who had had NYHA class III or IV heart failure for at least three months were eligible for screening. Patients were required to have been receiving standard therapy for heart failure, as determined to be appropriate by their physicians; such therapy included angiotensin-converting–enzyme inhibitors, angiotensin-receptor blockers, beta-blockers for at least three months before randomization, digoxin, spironolactone, and diuretics. Patients also had to have evidence of left ventricular dysfunction within the six months preceding randomization in the form of a resting left ventricular ejection fraction of no more than 35 percent or a resting left ventricular ejection fraction of less than 45 percent with a left ventricular internal end-diastolic diameter of more than 2.9 cm per square meter of body-surface area or more than 6.5 cm on the basis of echocardiography.
Women were excluded if they were pregnant, nursing, or of childbearing age and not using an effective method of contraception. The following were also reasons for exclusion: an acute myocardial infarction, acute coronary syndrome, or stroke within the preceding three months; cardiac surgery or percutaneous coronary intervention within the preceding three months or the likelihood of a requirement for such procedures during the study period; the presence of clinically significant valvular heart disease, hypertrophic or restrictive cardiomyopathy, active myocarditis, or uncontrolled hypertension; a history of cardiac arrest or life-threatening arrhythmias within the preceding three months (unless they had been treated with an implantable defibrillator); treatment with parenteral inotropic agents within one month before randomization; a potential need for cardiac transplantation; the presence of symptomatic hypotension; the presence of an illness other than heart failure that was likely to result in death within the study period; an inability to complete the quality-of-life questionnaire; and contraindications to the use of nitrate or hydralazine therapy.
Randomization Procedure
Randomization was performed centrally by Medifacts International, with stratification according to the use or nonuse of beta-blockers as background therapy. Blocks of 4 patients per stratum were used, with each site allowed to randomize up to 6 blocks of patients (24 patients) in the non–beta-blocker group and up to 10 blocks (40 patients) in the beta-blocker group.
Eligible patients were required to be receiving stable doses of therapy for heart failure and to have had a variation in body weight of less than 2.5 percent in the two weeks before randomization. At randomization, baseline evaluations included echocardiography, a metabolic profile, measurement of B-type natriuretic peptide and hemoglobin levels, and a quality-of-life questionnaire. After stratification according to the use or nonuse of beta-blockers as background therapy, patients were randomly assigned to receive a fixed-dose combination of isosorbide dinitrate plus hydralazine or to receive placebo, each in addition to background therapy. The initial dose was one tablet containing either placebo alone or 37.5 mg of hydralazine hydrochloride and 20 mg of isosorbide dinitrate three times daily. The dose was increased to two tablets three times daily, for a total daily dose of 225 mg of hydralazine hydrochloride and 120 mg of isosorbide dinitrate. An increase in the dose was dependent on the absence of drug-induced side effects as judged by the investigator. Patients were followed for up to 18 months, with assessment of the left ventricular ejection fraction, left ventricular internal diastolic dimension, left ventricular wall thickness, and level of B-type natriuretic peptide at 6 months and assessment of the quality of life every 3 months. Patients were interviewed by telephone monthly and returned for follow-up visits every three months.
Outcome Measures
The primary efficacy end point for the trial was a composite score made up of weighted values for death from any cause, a first hospitalization for heart failure during the 18-month follow-up period, and change in the quality of life at 6 months. The quality of life was assessed by means of the Minnesota Living with Heart Failure questionnaire, a 21-question self-administered instrument in which scores can range from 0 to 5 for each question, and higher scores indicate a poorer quality of life.42 The composite scoring system is shown in Table 1Table 1
Scoring System for the Primary Composite End Point..Secondary end points included individual components of the primary composite score, death from cardiovascular causes, the total number of hospitalizations for heart failure, the total number of hospitalizations for any reason, the total number of days of hospitalization, the overall quality of life throughout the trial, the number of unscheduled emergency room and office or clinic visits, the change in B-type natriuretic peptide level at six months, a newly recognized need for cardiac transplantation, and a change in the left ventricular ejection fraction, the left ventricular internal diastolic dimension, and the left ventricular wall thickness at six months. Data on patients who underwent cardiac transplantation during the trial were censored at the time of transplantation.
Statistical Analysis
Estimates of the sample size needed for the study to detect significant differences in the primary composite end point were based on data from V-HeFT I and II. Since the composite measure used in this trial had not been evaluated in previous trials, two interim analyses were prespecified in the protocol to permit an assessment of the adequacy of the sample size without knowledge of efficacy. The specific techniques for assessing the adequacy of the sample size were based on methods described by Cui et al.43 The data and safety monitoring board met four times during the trial and conducted the prespecified interim analyses. The initial estimate that 800 patients (400 per group) were needed for the study to have sufficient statistical power (P<0.02) was modified to 1100 patients (550 per group) in March 2003 on the basis of the prespecified interim analyses.
The primary efficacy comparison included all participants who had undergone randomization (intention-to-treat analysis). When data were missing, the worst-case score for that component of the composite end point was used in the primary analysis. The composite end point was compared between the groups with the use of a two-sample t-test.
The three individual components of the composite end point — death from any cause, first hospitalization for heart failure, and a change in the quality of life — were examined separately in secondary analyses. For the analysis of death from any cause, we used standard Kaplan–Meier survival methods with the log-rank test. These analyses included all randomized patients. We compared the incidence rates of death and of a first hospitalization for heart failure between groups using Fisher's exact test. We compared the change in the quality of life between groups using a two-sample t-test for the difference in scores (on the basis of the data obtained at six months or, when unavailable, data from the three-month assessment carried forward).
Additional descriptive statistics were estimated for patients' characteristics and reported as the mean (±SD) or the total number (and percentage). Adverse events were also compared between groups with the use of chi-square tests.
Results
Randomization was initiated on June 12, 2001, and the study was terminated on July 19, 2004, on the recommendation of the independent data and safety monitoring board after 1050 of the planned 1100 patients had undergone randomization — 518 to receive isosorbide dinitrate plus hydralazine and 532 to receive placebo. No patients were lost to follow-up.
The decision to stop the trial was based on the Lan–DeMets sequential-boundaries calculation.44 The trial was halted owing to a significantly higher mortality rate in the placebo group than in the group given isosorbide dinitrate plus hydralazine. At the time the trial was halted, 54 patients had died in the placebo group (10.2 percent) and 32 patients had died in the combination-therapy group (6.2 percent). There was a significant 43 percent improvement in survival (hazard ratio, 0.57; P=0.01 by the log-rank test). The mean duration of follow-up was 10 months (range, 0 to 18). The Kaplan–Meier survival analysis (Figure 1Figure 1
Kaplan–Meier Estimates of Overall Survival.) demonstrates that survival differences emerged at approximately 180 days and widened progressively thereafter (P=0.01 by the log-rank test).The baseline clinical characteristics of the patients are shown in Table 2Table 2
Baseline Characteristics.. At the termination of the trial, the primary composite score was –0.1±1.9 in the group given isosorbide dinitrate plus hydralazine, as compared with –0.5±2.0 in the placebo group (P=0.01), thus demonstrating a significant beneficial effect of nitric oxide–enhancing therapy (Table 3Table 3
End Points.). In addition to the reduction in the rate of death from any cause, the other individual components of the primary composite score were also significantly improved by treatment with isosorbide dinitrate and hydralazine (Table 3). The rate of first hospitalizations for heart failure was reduced by 33 percent, as compared with that in the placebo group (16.4 percent vs. 24.4 percent; 85 patients vs. 130 patients; P=0.001). The quality-of-life scores also improved more in the group given isosorbide dinitrate plus hydralazine than in the placebo group (–5.6±20.6 vs. –2.7±21.2, P=0.02).The composite end point was based on data on 1050 patients (the intention-to-treat population). A total of 742 patients filled out the quality-of-life questionnaire at six months. For all other patients, either an earlier post-baseline quality-of-life score was used or, if no such score was available, the patient received the worst possible score for the change in the quality of life (–2) as part of the composite end point.
The target dose was achieved in 68.0 percent of the patients in the group given isosorbide dinitrate plus hydralazine, as compared with 88.9 percent of the patients in the placebo group (P<0.001). The mean number of tablets per day was 3.8±2.5 in the group given isosorbide dinitrate plus hydralazine and 4.7±2.2 in the placebo group (P<0.001).
Combination therapy had a slight but significant blood-pressure–lowering effect at six months, decreasing systolic blood pressure by a mean of 1.9 mm Hg, as compared with an increase of 1.2 mm Hg in the placebo group (P=0.02), and decreasing diastolic blood pressure by a mean of 2.4 mm Hg, as compared with an increase of 0.8 mm Hg in the placebo group (P<0.001). There was no significant change in the heart rate between the two groups.
Adverse events are shown in Table 4Table 4
Adverse Events.. Symptoms of headache and dizziness were significantly more frequent in the group given isosorbide dinitrate plus hydralazine, whereas exacerbations of congestive heart failure (both moderate and severe) were significantly more frequent in the placebo group.Discussion
We confirmed the findings in V-HeFT I of the efficacy and survival advantage of a combination of isosorbide dinitrate plus hydralazine added to standard background therapy in patients with moderate-to-severe heart failure. The trial population was limited to patients who identified themselves as black, a subgroup that had had a particularly favorable response to this therapy in retrospective analyses.6,38
The 43 percent reduction in the mortality rate in the group given isosorbide dinitrate plus hydralazine occurred among patients who were well treated with a background regimen of neurohormonal-inhibitor drugs. Thus, the reduction in mortality is consistent with the existence of an alternative mechanism controlling the progression of heart failure. A similar reduction in mortality was previously reported among blacks with NYHA class II, III, or IV heart failure in V-HeFT I who were receiving only diuretics and digitalis rather than neurohormonal-inhibiting agents.6,38 These results suggest that a fixed-dose combination of isosorbide dinitrate plus hydralazine may benefit patients in a manner that is independent of background therapy.
Growing evidence supports the concept that nitric oxide protects against myocardial and vascular remodeling.11,22-27,45-47 The combination of isosorbide dinitrate and hydralazine may serve as a nitric oxide donor, with hydralazine conferring protection against the degradation of nitric oxide induced by oxidative stress.48-52 Thus, data from A-HeFT support, but do not prove, the existence of a protective role of nitric oxide even in the presence of neurohormonal blockade.
We used two strategies to demonstrate the efficacy of isosorbide dinitrate plus hydralazine as therapy for heart failure in a moderate-sized cohort. First, we designed the trial to include only patients self-identified as black, since previous data suggested that such patients had increased responsiveness to this therapy.6,38 Second, we used a composite score, composed of weighted values for death from any cause, a first adjudicated hospitalization for heart failure, and change in the quality of life, as the primary end point. We hypothesized that including in the primary end point data relevant to all important outcomes of chronic disease would enhance the statistical power of the study to detect efficacy in a moderate-sized cohort.53 The significant benefit of isosorbide dinitrate plus hydralazine demonstrated by the differences in the composite score (–0.1±1.9, as compared with –0.5±2.0 in the placebo group; P=0.01) provides support for the use of such an end point in future trials.
Nitric oxide regulates cardiovascular processes including myocardial hypertrophy, remodeling, and substrate use, as well as vascular function, inflammation, and thrombosis.11,22-27,45-47 Substantial evidence exists that endothelial dysfunction and impaired bioavailability of nitric oxide occur in both ischemic and nonischemic models of heart failure and contribute to the pathophysiology of congestive heart failure.12-19,21 Studies of murine models of heart failure — mice deficient in endothelial nitric oxide synthase and mice overexpressing nitric oxide synthase — have demonstrated the role of nitric oxide in preserving left ventricular performance, inhibiting myocardial remodeling, and improving survival.23,24,27,46 Nitric oxide has also been shown to regulate the use of myocardial substrate47 and mitochondrial respiration.25 In clinical models of heart failure, basal cardiac release of nitric oxide is decreased,54 sensitivity to inhibition of nitric oxide synthase is increased,55 nitric oxide–mediated processes are impaired,12,13,18 and oxidative stress is increased.14,15,17,19,20
Our choice of a study cohort of patients identifying themselves as black is based on observations of differences in prevalence, risk profiles, causation, disease severity, outcomes, and response to therapy between black patients and white patients with heart failure.28-30 Retrospective analyses according to race in V-HeFT I, V-HeFT II, and the Studies of Left Ventricular Dysfunction have shown significant differences between blacks and whites in the response to pharmacotherapy for heart failure.30,38,39 In a novel experimental system, Kalinowski et al.37 found that, as compared with endothelial cells from healthy white women, endothelial cells from healthy black women had diminished bioavailability of nitric oxide as a result of increased oxidative stress. Data suggesting that endothelial function and bioavailability of nitric oxide may be less robust in blacks than in whites32-37 lend credibility to the hypothesis that the balance of mechanisms leading to the progression of heart failure may vary with geographic origin.
The combination of isosorbide dinitrate and hydralazine was used as a vasodilator in V-HeFT I because of its balanced effect on arteriolar dilation and venodilation. Once the physiologic role of nitric oxide was elucidated, it became apparent that isosorbide dinitrate exerts its vasodilatory effect by donating nitric oxide or forming related compounds.48,56 Concomitant administration of hydralazine prolongs the vasodilatory effects of isosorbide dinitrate in experimental and clinical models.19,49-52 Munzel et al.51 have shown that hydralazine is an effective antioxidant, inhibiting the generation of nitric oxide–inactivating reactive oxygen species by inhibiting vascular NADH and NADPH oxidases. Similarly, other antioxidants have been shown to reduce the mitochondrial production of reactive oxygen species.57 Thus, hydralazine, by reducing oxidative stress, may enhance the effects of nitric oxide derived from nitric oxide donors as well as from endogenous sources. This study, however, does not establish that these mechanisms explain the clinical benefit of isosorbide dinitrate plus hydralazine in heart failure.
Our trial represents a departure from the recent approach to the design of cardiovascular trials. Rather than studying a large heterogeneous population, we examined a specific population in whom efficacy was more likely to be established. A heterogeneous population may have substantial variations in genetic and environmental factors that influence disease progression and the response to therapy. Since subgroups of the trial cohort are rarely large enough for statistical analyses of the heterogeneity of an effect, the standard thinking is that the overall response to therapy should be accepted as a mandate for the use of that therapy in all subgroups in the trial. Recent insights into mechanistic variability, however, lend credence to the concept that the average effects in heterogeneous populations may obscure therapeutic efficacy in some subgroups and the lack of such efficacy in others.
Our finding of the efficacy of isosorbide dinitrate plus hydralazine in black patients provides strong evidence that this therapy can slow the progression of heart failure. A future strategy would be to identify genotypic and phenotypic characteristics that would transcend racial or ethnic categories to identify a population with heart failure in which there is an increased likelihood of a favorable response to such therapy.
Supported by NitroMed.
Dr. Cohn was the inventor on two patents (6,784,177 and 6,465,463) for the use of combinations of hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate in heart failure. In return for equity and potential future royalties, NitroMed licensed from him the patent for mortality reduction of the drug combination in heart failure. NitroMed subsequently applied for a patent for use in black patients. Dr. Anne Taylor, Ms. Ziesche, and Dr. Adams have received research support from NitroMed. Dr. Yancy has received consulting and lecture fees from the company. Drs. Sabolinski and Worcel are employees of the company, in which they and Ms. Ziesche own equity. Dr. Anne Taylor reports having served as a consultant to Wyeth–Ayerst and Bristol-Myers Squibb. Dr. Yancy reports having received consulting and lecture fees from GlaxoSmithKline, Scios, and Medtronic. Dr. Carson reports having received consulting fees from and having served on paid advisory boards for Bristol-Myers Squibb, Pfizer, NitroMed, AstraZeneca, GlaxoSmithKline, Guidant, and Myogen and having received lecture fees from AstraZeneca, Bristol-Myers Squibb/Sanofi, and Novartis. Dr. D'Agostino reports having received consulting fees from Target Health and having been the independent statistician who performed the analysis for the study and who was paid by Target Health, which billed NitroMed. Dr. Ferdinand reports having received consulting fees from Pfizer and AstraZeneca and lecture fees from Pfizer, AstraZeneca, and Merck. Dr. Malcolm Taylor reports having received consulting fees from Pfizer and GlaxoSmithKline and lecture fees from GlaxoSmithKline and AstraZeneca. Dr. Cohn reports having received consulting fees and an advisory-board membership from NitroMed, Novartis, Amgen, and Medtronics; equity ownership and stock options from Hypertension Diagnostics; and research support from Novartis.
We are indebted to the Association of Black Cardiologists, whose partnership facilitated the conduct of the trial, and to Ms. Kristine Olson for her assistance in the preparation of the manuscript.
Source Information
From the University of Minnesota (A.L.T., J.N.C.) and Minneapolis Veterans Affairs Hospital (S.Z.) — both in Minneapolis; University of Texas Southwestern Medical Center, Dallas (C.Y.); Veterans Affairs Medical Center, Washington, D.C. (P.C.); Wake Forest University, School of Medicine, Winston-Salem, N.C. (R.D.); Heartbeats Life Center and Xavier University, New Orleans (K.F.); Jackson Cardiology Associates, Jackson, Miss. (M.T.); Association of Black Cardiologists, Atlanta (M.T.); University of North Carolina, Chapel Hill (K.A.); and NitroMed, Lexington, Mass. (M.S., M.W.).
Address reprint requests to Dr. Anne Taylor at the Department of Medicine/Cardiology, University of Minnesota Medical School, 420 Delaware St. SE, MMC 293, Minneapolis, MN 55455, or at taylo135@umn.edu.
Participants in the African-American Heart Failure Trial (A-HeFT) are listed in the Appendix.
Appendix
The A-HeFT included the following: Steering Committee — A.L. Taylor (chair), K. Adams, P. Carson, J.N. Cohn, K. Ferdinand, E. Ofili, A. Olukotun, M. Taylor, C. Yancy, and S. Ziesche; Data and Safety Monitoring Committee — D. DeMets (chair), R. Grimm, P. Ouyang, J.T. Wright, Jr., R. D'Agostino, Jr., and M. Walkup (independent statisticians); Independent Adjudication Committee — P. Carson, A.B. Miller, J. Lindenfeld, C. O'Connor, F. Tristani, J. Ghali, and I. Anand; Participating Investigators — J. Adams, K. Adams, T. Addai, A. Amanullah, I. Anand, J. Anderson, J. Babb, L.Bass, A. Bazzi, H. Benipal, S.K. Bennett, W. Bennett, M. Berk, R. Berry, H. Bhatia, A. Bouchard, J. Boutros, S. Broadwater, C.S. Brown, K. Brown, K. Burnham, J. Butler, L. Campos, D. Chapman, D. Chomsky, F. Cobb, R. Cooke, C. Corder, K.M. Coy, L. Crawford, G. Crossley, C. Curry, K.G. Curry, B. Czerska, P.H. D'Amato, K.N. Dave, V. Dave, J. Dean, R. Delgado, S. Desai, A. Deswal, W. Drummond, M. Dunlap, L.C. Egbujiobi, U. El Kayam, J. Farahi, R. Fei, K. Ferdinand, Gary Fishbein, S.J. Fitzmorris, J. Flack, M. Garg, R. Gelzer-Bell, J. Ghali, S. Goldsmith, S. Gottleib, I. Gradus-Pizlo, B. Grant-Anderson, B.A. Graves, M. Greenberg, D. Gupta, E. Hamilton, S. Hankins, J. Hargrove, B.L. Harris, R. Harrison, K. Hebert, K. Taylor, A. Herioux, J. Hernandez, M. Hess, J.T. Heywood, G. Hillard, C. Hunter, S.W. Hutchins, H.M. Ibrahim, D. Ike, C.S. Ince, Jr., C. Israel, J. Joseph, A. Kaneshige, S. Katz, A. Khan, S. Khan, M. Klapholz, D. Knox, M. Krolick, M. Kukin, A. Kumar, K. Kutoloski, B. Lachterman, R. Lang, D. Lewis, R. Lewis, I. Lieber, C.F. Lovell, J. Tift Mann, O. Maytin, F. McGrew, M. McIvor, H. Meilman, G. Mikdadi, A. Miller, C.K. Moore, D. Moraes, T.E. Motley, Sr., M. Nallasivan, A. Niederman, A. Oduwole, E. Ofili, J. Olowoyeye, L. O'Meallie, A. Onwukwe, S. Patel, D. Pauly, D. Pearce, G. Perry, D. Phillips, I. Pina, R. Player. D.S. Primack, L.M. Prisant, M. Ptacin, J.A. Puma, J. Quartner, M.I. Rana, L. Reiss, H. Ribner, R. Rigmaiden, J.G. Rogers, J. Rozanski, M. Rubinstein, A. Saenz, L. Salciccioli, F. Sam, G.T. Schuyler, E. Schwarz, C.L. Scott, M. Shah, K. Sheikh, V. Singh, A.L. Smith, R. Smith, J.C. Sobolski, A. Soffer, R. Soucier, A. Stern, J. Tallaj, W.R. Taylor, U. Thadani, G. Torre, R.A. Townsend, P. Underwood, A. Van Bakel, L. Wagoner, J. Wallia, M. Walsh, A.L. Warner, R. Workman, and C. Yancy.
- References
References
1
The CONSENSUS Trial Study Group
Full Text | Web of Science | Medline2
Pfeffer MA ,Braunwald E ,Moye LA , et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-677
Full Text | Web of Science | Medline3
Packer M ,Coats AJS ,Fowler MB , et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658
Full Text | Web of Science | Medline4
Effect of metoprolol CF/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007
CrossRef | Web of Science | Medline5
Dries DL ,Strong MH ,Cooper RS ,Drazner MH . Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 2002;40:311-317[Erratum, J Am Coll Cardiol 2002;40:1019.]
CrossRef | Web of Science | Medline6
Cohn JN ,Archibald DG ,Ziesche S , et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-1552
Full Text | Web of Science | Medline7
Cohn JN ,Johnson G ,Ziesche S , et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310
Full Text | Web of Science | Medline8
Cohn JN ,Tognoni G . A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675
Full Text | Web of Science | Medline9
Yancy CW ,Fowler MB ,Colucci WS , et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001;344:1358-1365
Full Text | Web of Science | Medline10
The Beta-Blocker Evaluation of Survival Trial Investigators
Full Text | Web of Science | Medline11
Cai H ,Harrison DG . Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-844
Web of Science | Medline12
Drexler H ,Hayoz D ,Munzel T , et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992;69:1596-1601
CrossRef | Web of Science | Medline13
Wang J ,Seyedi N ,Xu XB ,Wolin MS ,Hintze TH . Defective endothelium mediated control of coronary circulation in conscious dogs after heart failure. Am J Physiol 1994;266:H670-H680
Web of Science | Medline14
Sharma R ,Davidoff MN . Oxidative stress and endothelial dysfunction in heart failure. Congest Heart Fail 2002;8:165-172
CrossRef | Medline15
Diaz-Velez CR ,Garcia-Castineiras S ,Mendoza-Ramos E ,Hernandez-Lopez E . Increased malondialdehyde peripheral blood of patients with congestive heart failure. Am Heart J 1996;131:146-152
CrossRef | Web of Science | Medline16
Keith M ,Geranmayegan A ,Sole MJ , et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998;31:1352-1356
CrossRef | Web of Science | Medline17
Belch JJ ,Bridges AB ,Scott N ,Chopra M . Oxygen free radicals and congestive heart failure. Br Heart J 1991;65:245-248
CrossRef | Web of Science | Medline18
Kubo SH ,Rector TS ,Bank AJ ,Williams RE ,Heifetz SM . Endothelium dependent vasodilation is attenuated in patients with heart failure. Circulation 1991;84:1589-1596
Web of Science | Medline19
Munzel T ,Harrison DG . Increased superoxide in heart failure: a biochemical baroreflex gone awry. Circulation 1999;100:216-218
Web of Science | Medline20
Gryglewski RJ ,Palmer RM ,Moncada S . Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-456
CrossRef | Web of Science | Medline21
Dixon LJ ,Morgan DR ,Hughes SM , et al. Functional consequences of endothelial nitric oxide synthase uncoupling in congestive cardiac failure. Circulation 2003;107:1725-1728
CrossRef | Web of Science | Medline22
Prabhu SD . Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart. Circ Res 2004;94:1155-1157
CrossRef | Web of Science | Medline23
Janssens S ,Pokreisz P ,Schoonjans L , et al. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 2004;94:1256-1262
CrossRef | Web of Science | Medline24
Scherrer-Crosbie M ,Ullrich R ,Bloch KD , et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 2001;104:1286-1291
CrossRef | Web of Science | Medline25
Loke KE ,Laycock SK ,Mital S , et al. Nitric oxide modulates mitochondrial respiration in failing human heart. Circulation 1999;100:1291-1297
Web of Science | Medline26
Drexler H . Nitric oxide synthases in the failing human heart: a double-edged sword. Circulation 1999;99:2972-2975
Web of Science | Medline27
Jones SP ,Greer JJM ,van Haperen R ,Duncker DJ ,de Crom R ,Lefer DJ . Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci U S A 2003;100:4891-4896
CrossRef | Web of Science | Medline28
Yancy CW . Does race matter in heart failure? Am Heart J 2003;146:203-206
CrossRef | Web of Science | Medline29
Yancy CW . Heart failure in African Americans: a cardiovascular enigma. J Card Fail 2000;6:183-186
CrossRef | Web of Science | Medline30
Dries DL ,Exner DV ,Gersh BJ ,Cooper HA ,Carson PE ,Domanski MJ . Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999;340:609-616[Erratum, N Engl J Med 1999;341:298.]
Full Text | Web of Science | Medline31
Gillum RF . Pathophysiology of hypertension in blacks and whites: a review of the basis of racial blood pressure differences. Hypertension 1979;1:468-475
Web of Science | Medline32
Cardillo C ,Kilcoyne CM ,Cannon RO III ,Panza JA . Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. Hypertension 1998;31:1235-1239
Web of Science | Medline33
Stein CM ,Lang CC ,Nelson R ,Brown M ,Wood AJ . Vasodilation in black Americans: attenuated nitric oxide-mediated responses. Clin Pharmacol Ther 1997;62:436-443
CrossRef | Web of Science | Medline34
Hinderliter AL ,Sager AR ,Sherwood A ,Light KC ,Girdler SS ,Willis PW IV . Ethnic differences in forearm vasodilator capacity. Am J Cardiol 1996;78:208-211
CrossRef | Web of Science | Medline35
Kahn D ,Duff SJ ,Tomasian D , et al. Effects of black race on forearm resistance vessel function. Hypertension 2002;40:195-201
CrossRef | Web of Science | Medline36
Houghton JL ,Smith VE ,Strogatz DS ,Henches NL ,Breisblatt WM ,Carr AA . Effect of African-American race and hypertensive left ventricular hypertrophy on coronary vascular reactivity and endothelial function. Hypertension 1997;29:706-714
Web of Science | Medline37
Kalinowski L ,Dobrucki I ,Malinski T . Race-specific differences in endothelial function: predisposition of African Americans to vascular disease. Circulation 2004;109:2511-2517
CrossRef | Web of Science | Medline38
Carson P ,Ziesche S ,Johnson G ,Cohn JN . Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 1999;5:178-187
CrossRef | Medline39
Exner DV ,Dries DL ,Domanski MJ ,Cohn JN . Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-1357
Full Text | Web of Science | Medline40
Franciosa JA ,Taylor AL ,Cohn JN , et al. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail 2002;8:128-135
CrossRef | Web of Science | Medline41
Taylor AL . The African-American Heart Failure Trial (A-HeFT): rationale and methodology. J Card Fail 2003;9:Suppl:S216-S219[Erratum, J Card Fail 2003;9:481.]
CrossRef | Web of Science | Medline42
Rector TS ,Cohn JN . Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J 1992;124:1017-1025
CrossRef | Web of Science | Medline43
Cui L ,Hung HMJ ,Wang SJ . Modification of sample size in group sequential clinical trials. Biometrics 1999;55:853-857
CrossRef | Web of Science | Medline44
Lan KKG ,Reboussin DM ,DeMets DL . Information and informational fractions for design and sequential monitoring of clinical trials. Comm Stat Theory Methods 1994;23:403-420
CrossRef | Web of Science45
Harrison DG . Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997;100:2153-2157
CrossRef | Web of Science | Medline46
Liu YH ,Xu J ,Yang XP ,Yang F ,Shesely E ,Carretero OA . Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure. Hypertension 2002;39:375-381
CrossRef | Web of Science | Medline47
Recchia FA ,Osorio JC ,Chandler MP , et al. Reduced synthesis of NO causes marked alterations in myocardial substrate metabolism in conscious dogs. Am J Physiol Endocrinol Metab 2002;282:E197-E206
Web of Science | Medline48
Ignarro LJ ,Napoli C ,Loscalzo J . Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 2002;90:21-28
CrossRef | Web of Science | Medline49
Bauer JA ,Fung HL . Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation 1991;84:35-39
Web of Science | Medline50
Gogia H ,Mehra A ,Parikh S , et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol 1995;26:1575-1580
CrossRef | Web of Science | Medline51
Munzel T ,Kurz S ,Rajagopalan S , et al. Hydralazine prevents nitroglycerine tolerance by inhibiting activation of a membrane-bound NADH oxidase: a new action for an old drug. J Clin Invest 1996;98:1465-1470
CrossRef | Web of Science | Medline52
McVeigh GE ,Hamilton P ,Wilson M , et al. Platelet nitric oxide and superoxide release during the development of nitrate tolerance: effect of supplemental ascorbate. Circulation 2002;106:208-213
CrossRef | Web of Science | Medline53
Packer M . Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail 2001;7:176-182
CrossRef | Web of Science | Medline54
Mohri M ,Egashira K ,Tagawa T , et al. Basal release of nitric oxide is decreased in the coronary circulation in patients with heart failure. Hypertension 1997;30:50-56
Web of Science | Medline55
Hare JM ,Givertz MM ,Creager MA ,Colucci WS . Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness. Circulation 1998;97:161-166
Web of Science | Medline56
Chen Z ,Zhang J ,Stamler JS . Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A 2002;99:8306-8311
CrossRef | Web of Science | Medline57
Sydow K ,Daiber A ,Oelze M , et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 2004;113:482-489
Web of Science | Medline
- Citing Articles (375)
Citing Articles
1
Ajith P. Nair, Tendoh Timoh, Valentin Fuster. (2012) Contemporary Medical Management of Systolic Heart Failure. Circulation Journal 76:2, 268-277
CrossRef2
Kamen P. Valchanov, Joseph E. Arrowsmith. (2012) The role of venodilators in the perioperative management of heart failure. European Journal of Anaesthesiology1
CrossRef3
Norimichi Koitabashi, David A. Kass. (2011) Reverse remodeling in heart failure—mechanisms and therapeutic opportunities. Nature Reviews Cardiology
CrossRef4
Francesco Iachini Bellisarii, Francesco Radico, Francesca Muscente, John Horowitz, Raffaele De Caterina. (2011) Nitrates and Other Nitric Oxide Donors in Cardiology - Current Positioning and Perspectives. Cardiovascular Drugs and Therapy
CrossRef5
Matthias Dupont, Wilfried Mullens, W. H. Wilson Tang. (2011) Impact of Systemic Venous Congestion in Heart Failure. Current Heart Failure Reports 8:4, 233-241
CrossRef6
John T. Parissis, Pinelopi Rafouli-Stergiou, Alexandre Mebazaa, Ignatios Ikonomidis, Vassiliki Bistola, Maria Nikolaou, Taly Meas, Juan Delgado, Fabio Vilas-Boas, Ioannis Paraskevaidis, Maria Anastasiou-Nana, Ferenc Follath. (2011) Acute heart failure in patients with diabetes mellitus: Clinical characteristics and predictors of in-hospital mortality. International Journal of Cardiology
CrossRef7
Joel Handler. (2011) Hydralazine-Induced Lupus Erythematosis. The Journal of Clinical Hypertensionno-no
CrossRef8
Andreas P. Kalogeropoulos, Vasiliki V. Georgiopoulou, Mihai Gheorghiade, Javed Butler. (2011) Echocardiographic Evaluation of Left Ventricular Structure and Function: New Modalities and Potential Applications in Clinical Trials. Journal of Cardiac Failure
CrossRef9
E. de Teresa Galván, J.M. García Pinilla, R. de Teresa Herrera. (2011) Tratamiento de la insuficiencia cardiaca. Medicine - Programa de Formación Médica Continuada Acreditado 10:92, 6240-6248
CrossRef10
Daniel Jacoby, Oltjan Albajrami, Lavanya Bellumkonda. (2011) Natural History of End-stage LV Dysfunction: Has It Improved from the Classic Franciosa and Cohn Graph?. Cardiology Clinics 29:4, 485-495
CrossRef11
Eitan Amir, Bostjan Seruga, Ryan Kwong, Ian F. Tannock, Alberto Ocaña. (2011) Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?. European Journal of Cancer
CrossRef12
Jonathan P. Man, Bodh I. Jugdutt. (2011) Systolic heart failure in the elderly: optimizing medical management. Heart Failure Reviews
CrossRef13
Frank Peacock, Alpesh Amin, Christopher B. Granger, Charles V. Pollack, Phillip Levy, Richard Nowak, Kurt Kleinschmidt, Joe Varon, Allison Wyman, Joel M. Gore. (2011) Hypertensive heart failure: patient characteristics, treatment, and outcomes. The American Journal of Emergency Medicine 29:8, 855-862
CrossRef14
Marie Galvao. (2011) Underrepresentation of minorities in clinical trials: A current problem with escalating future implications. Heart & Lung: The Journal of Acute and Critical Care 40:5, 391-392
CrossRef15
Marco A. Caccamo, Peter M. Eckman. (2011) Pharmacologic Therapy for New York Heart Association Class IV Heart Failure. Congestive Heart Failure 17:5, 213-219
CrossRef16
Jay N. Cohn, Gordon T. McInnes, Alexander M. Shepherd. (2011) Direct-Acting Vasodilators. The Journal of Clinical Hypertension 13:9, 690-692
CrossRef17
Charles F. Jackson, Nanette K. Wenger. (2011) Enfermedad cardiovascular en el anciano. Revista Española de Cardiología 64:8, 697-712
CrossRef18
Henry Krum, John R Teerlink. (2011) Medical therapy for chronic heart failure. The Lancet 378:9792, 713-721
CrossRef19
Charles F. Jackson, Nanette K. Wenger. (2011) Cardiovascular Disease in the Elderly. Revista Española de Cardiología (English Edition) 64:8, 697-712
CrossRef20
Pat Matthews-Juarez, Paul D. Juarez. (2011) Cultural Competency, Human Genomics, and the Elimination of Health Disparities. Social Work in Public Health 26:4, 349-365
CrossRef21
Wilbert S. Aronow, Jerome L. Fleg, Carl J. Pepine, Nancy T. Artinian, George Bakris, Alan S. Brown, Keith C. Ferdinand, Mary Ann Forciea, William H. Frishman, Cheryl Jaigobin, John B. Kostis, Giuseppi Mancia, Suzanne Oparil, Eduardo Ortiz, Efrain Reisin, Michael W. Rich, Douglas D. Schocken, Michael A. Weber, Deborah J. Wesley, Robert A. Harrington, Eric R. Bates, Deepak L. Bhatt, Charles R. Bridges, Mark J. Eisenberg, Victor A. Ferrari, John D. Fisher, Timothy J. Gardner, Federico Gentile, Michael F. Gilson, Mark A. Hlatky, Alice K. Jacobs, Sanjay Kaul, David J. Moliterno, Debabrata Mukherjee, Robert S. Rosenson, James H. Stein, Howard H. Weitz, Deborah J. Wesley. (2011) ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American Society of Hypertension 5:4, 259-352
CrossRef22
Judith E. Mitchell, S. William Tam, Kamini Trivedi, Anne L. Taylor, Welton O'Neal, Jay N. Cohn, Manuel Worcel. (2011) Atrial fibrillation and mortality in African American patients with heart failure: Results from the African American Heart Failure Trial (A-HeFT). American Heart Journal 162:1, 154-159
CrossRef23
Ilya Lipkovich, Alex Dmitrienko, Jonathan Denne, Gregory Enas. (2011) Subgroup identification based on differential effect search-A recursive partitioning method for establishing response to treatment in patient subpopulations. Statistics in Medicinen/a-n/a
CrossRef24
Gregory Giamouzis, Javed Butler, Filippos Triposkiadis. (2011) Renal Function in Advanced Heart Failure. Congestive Heart Failure 17:4, 180-188
CrossRef25
H. M. James Hung, Sue-Jane Wang, Robert O'Neill. (2011) Flexible design clinical trial methodology in regulatory applications. Statistics in Medicine 30:13, 1519-1527
CrossRef26
Nicholas J. Leeper, Reza Ardehali, Michael Fowler. 2011. Care of the Cardiomyopathic Patient. , 67-80.
CrossRef27
Alex Reyentovich, Stuart D. Katz. (2011) Mineralocorticoid-receptor Antagonists in Heart Failure: A Tale of Serendipity and Success. Current Heart Failure Reports 8:2, 87-90
CrossRef28
Sandhya Murthy, Hannah I. Lipman. (2011) Management of End-Stage Heart Failure. Primary Care: Clinics in Office Practice 38:2, 265-276
CrossRef29
Lynne Warner Stevenson. (2011) Projecting heart failure into bankruptcy in 2012?. American Heart Journal 161:6, 1007-1011
CrossRef30
Gregg C. Fonarow, Clyde W. Yancy, Adrian F. Hernandez, Eric D. Peterson, John A. Spertus, Paul A. Heidenreich. (2011) Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. American Heart Journal 161:6, 1024-1030.e3
CrossRef31
Ryan P. Morrissey, Lawrence Czer, Prediman K. Shah. (2011) Chronic Heart Failure. American Journal Cardiovascular Drugs 11:3, 153-171
CrossRef32
Nicholas B Norgard, Gina M Prescott. (2011) Future of personalized pharmacotherapy in chronic heart failure patients. Future Cardiology 7:3, 357-379
CrossRef33
Wilbert S. Aronow, Jerome L. Fleg, Carl J. Pepine, Nancy T. Artinian, George Bakris, Alan S. Brown, Keith C. Ferdinand, Mary Ann Forciea, William H. Frishman, Cheryl Jaigobin, John B. Kostis, Giuseppi Mancia, Suzanne Oparil, Eduardo Ortiz, Efrain Reisin, Michael W. Rich, Douglas D. Schocken, Michael A. Weber, Deborah J. Wesley. (2011) ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American College of Cardiology 57:20, 2037-2114
CrossRef34
Jay N. Cohn. (2011) Pharmacotherapy: Inhibiting LV remodeling—the need for a targeted approach. Nature Reviews Cardiology 8:5, 248-249
CrossRef35
J. Robert. (2011) Vers une prescription individualisée des traitements anticancéreux. Journal Africain du Cancer / African Journal of Cancer 3:1, 1-2
CrossRef36
William T Abraham, Philip B Adamson, Robert C Bourge, Mark F Aaron, Maria Rosa Costanzo, Lynne W Stevenson, Warren Strickland, Suresh Neelagaru, Nirav Raval, Steven Krueger, Stanislav Weiner, David Shavelle, Bradley Jeffries, Jay S Yadav. (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. The Lancet 377:9766, 658-666
CrossRef37
Chiara Nediani, Laura Raimondi, Elisabetta Borchi, Elisabetta Cerbai. (2011) Nitric Oxide/Reactive Oxygen Species Generation and Nitroso/Redox Imbalance in Heart Failure: From Molecular Mechanisms to Therapeutic Implications. Antioxidants & Redox Signaling 14:2, 289-331
CrossRef38
Christopher J. Hogan, Kevin R. Ward, Michael C. Kontos, Leroy R. Thacker, Roland Pittman. (2011) Peripheral tissue oxygenation improves during ED treatment of acute heart failure
. The American Journal of Emergency Medicine
CrossRef39
M. Demede, A. Pandey, L. Innasimuthu, G. Jean-Louis, S. I. McFarlane, G. Ogedegbe. (2011) Management of Hypertension in High-Risk Ethnic Minority with Heart Failure. International Journal of Hypertension 2011, 1-8
CrossRef40
Catherine Olivier, Bryn Williams-Jones. (2011) Pharmacogenomic technologies: a necessary "luxury" for better global public health?. Globalization and Health 7:1, 30
CrossRef41
Arjen E de Vries, Richard M de Jong, Martje HL van der Wal, Tiny Jaarsma, Rene B van Dijk, Hans L Hillege. (2011) The value of INnovative ICT guided disease management combined with Telemonitoring in OUtpatient clinics for Chronic Heart failure patients. Design and methodology of the IN TOUCH study: a multicenter randomised trial. BMC Health Services Research 11:1, 167
CrossRef42
Lionel D. Edwards, J-M. Husson, E. Labbé, C. Naito, M. Papaluca Amati, S. Walker, R. L. Williams, H. Yasurhara. 2010. Racial and Ethnic Issues in Drug Regulation. , 233-249.
CrossRef43
Lisa Gannett. (2010) Questions asked and unasked: how by worrying less about the ‘really real’ philosophers of science might better contribute to debates about genetics and race. Synthese 177:3, 363-385
CrossRef44
Keith A Thompson, Parag Bharadwaj, Kiran J Philip, Ernst R Schwarz. (2010) Heart failure therapy: beyond the guidelines. Journal of Cardiovascular Medicine 11:12, 919-927
CrossRef45
R Temple. (2010) Enrichment of Clinical Study Populations. Clinical Pharmacology & Therapeutics 88:6, 774-778
CrossRef46
Keyur B. Shah, Willem J. Kop, Robert H. Christenson, Deborah B. Diercks, Dick Kuo, Sue Henderson, Karen Hanson, Christopher R. deFilippi. (2010) Post-discharge changes in NT-proBNP and quality of life after acute dyspnea hospitalization as predictors of one-year outcomes. Clinical Biochemistry 43:18, 1405-1410
CrossRef47
Yoshiko Mizuno, Robert F. Jacob, R. Preston Mason. (2010) Advances in Pharmacologic Modulation of Nitric Oxide in Hypertension. Current Cardiology Reports 12:6, 472-480
CrossRef48
Vijay U. Rao, John R. Teerlink. 2010. Treating Systolic Heart Failure. , 287-326.
CrossRef49
Dawn Lombardo. 2010. Digoxin, Diuretics, and Vasodilators in Heart Failure. , 117-135.
CrossRef50
Giovanna Branzi, Gabriella Malfatto, Alessandra Villani, Francesca Ciambellotti, Miriam Revera, Alessia Giglio, Francesco Della Rosa, Mario Facchini, Gianfranco Parati. (2010) Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure. Journal of Cardiovascular Medicine 11:9, 662-668
CrossRef51
Christian Ukena, Andreas Link, Michael Böhm. (2010) NO-Donatoren bei der Therapie der Herzinsuffizienz. Größtes Problem: Toleranzentwicklung. Pharmazie in unserer Zeit 39:5, 369-373
CrossRef52
Thomas Münzel, Eberhard Schulz. (2010) Therapie der koronaren Herzerkrankung mit NO-Donatoren. Nach wie vor eine wichtige Option. Pharmazie in unserer Zeit 39:5, 359-368
CrossRef53
Javed Butler, Inder S. Anand, Michael A. Kuskowski, Thomas Rector, Peter Carson, Jay N. Cohn, . (2010) Digoxin Use and Heart Failure Outcomes: Results from the Valsartan Heart Failure Trial (Val-HeFT). Congestive Heart Failure 16:5, 191-195
CrossRef54
Melanie E Armitage, Mylinh La, Harald HHW Schmidt, Kirstin Wingler. (2010) Diagnosis and individual treatment of cardiovascular diseases: targeting vascular oxidative stress. Expert Review of Clinical Pharmacology 3:5, 639-648
CrossRef55
Finn Gustafsson, Julian Segura, Luis M Ruilope. (2010) How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?. Journal of Hypertension 28:8, 1595-1598
CrossRef56
Rui-Hai Zhou, William H. Frishman. (2010) The Antiplatelet Effects of Nitrates. Cardiology in Review 18:4, 198-203
CrossRef57
A. Davenport, S. D. Anker, A. Mebazaa, A. Palazzuoli, G. Vescovo, R. Bellomo, P. Ponikowski, I. Anand, N. Aspromonte, S. Bagshaw, T. Berl, I. Bobek, D. N. Cruz, L. Daliento, M. Haapio, H. Hillege, A. House, N. Katz, A. Maisel, S. Mankad, P. McCullough, F. Ronco, A. Shaw, G. Sheinfeld, S. Soni, N. Zamperetti, P. Zanco, C. Ronco, . (2010) ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference. Nephrology Dialysis Transplantation 25:7, 2077-2089
CrossRef58
Daniel G. Kramer, Thomas A. Trikalinos, David M. Kent, George V. Antonopoulos, Marvin A. Konstam, James E. Udelson. (2010) Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American College of Cardiology 56:5, 392-406
CrossRef59
Meredith O. Cruz, Joan Briller, Judith U. Hibbard. (2010) Update on Peripartum Cardiomyopathy. Obstetrics and Gynecology Clinics of North America 37:2, 283-303
CrossRef60
(2010) Section 13: Evaluation and Therapy for Heart Failure in the Setting of Ischemic Heart Disease. Journal of Cardiac Failure 16:6, e157-e165
CrossRef61
(2010) Section 7: Heart Failure in Patients With Reduced Ejection Fraction. Journal of Cardiac Failure 16:6, e73-e97
CrossRef62
(2010) Section 15: Management of Heart Failure in Special Populations. Journal of Cardiac Failure 16:6, e169-e175
CrossRef63
Dennis Schade, Jürke Kotthaus, Bernd Clement. (2010) Modulating the NO generating system from a medicinal chemistry perspective: Current trends and therapeutic options in cardiovascular disease. Pharmacology & Therapeutics 126:3, 279-300
CrossRef64
N. Sangala, R. W. Lee, C. Horsfield, D. J. A. Goldsmith. (2010) Combined ANCA-associated vasculitis and lupus syndrome following prolonged use of hydralazine: a timely reminder of an old foe. International Urology and Nephrology 42:2, 503-506
CrossRef65
Heart Failure Society of America. (2010) Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure 16:6, 475-539
CrossRef66
Bodh I Jugdutt. (2010) Heart failure in the elderly: advances and challenges. Expert Review of Cardiovascular Therapy 8:5, 695-715
CrossRef67
Jula K. Inrig. (2010) Antihypertensive Agents in Hemodialysis Patients: A Current Perspective. Seminars in Dialysis 23:3, 290-297
CrossRef68
Danielle Frank, Thomas H. Gallagher, Sherrill L. Sellers, Lisa A. Cooper, Eboni G. Price, Adebola O. Odunlami, Vence L. Bonham. (2010) Primary Care Physicians’ Attitudes Regarding Race-Based Therapies. Journal of General Internal Medicine 25:5, 384-389
CrossRef69
Yuliy Y. Chirkov, Michele Sciscio, Aaron L. Sverdlov, Sue Leslie, Peter R. Sage, John D. Horowitz. (2010) Hydralazine does not Ameliorate Nitric Oxide Resistance in Chronic Heart Failure. Cardiovascular Drugs and Therapy 24:2, 131-137
CrossRef70
Anju Bhardwaj, Shafiq U. Rehman, Asim Mohammed, Aaron L. Baggish, Stephanie A. Moore, James L. Januzzi. (2010) Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. American Heart Journal 159:4, 532-538.e1
CrossRef71
Jonathan G. Howlett, Robert S. McKelvie, Jeannine Costigan, Anique Ducharme, Estrellita Estrella-Holder, Justin A. Ezekowitz, Nadia Giannetti, Haissam Haddad, George A. Heckman, Anthony M. Herd, Debra Isaac, Simon Kouz, Kori Leblanc, Peter Liu, Elizabeth Mann, Gordon W. Moe, Eileen O’Meara, Miroslav Rajda, Samuel Siu, Paul Stolee, Elizabeth Swiggum, Shelley Zeiroth. (2010) The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. Canadian Journal of Cardiology 26:4, 185-202
CrossRef72
Michael Oettel. 2010. The Promise of Individualized Therapy. .
CrossRef73
Gordon W Moe, Jack Tu. (2010) Heart failure in the ethnic minorities. Current Opinion in Cardiology 25:2, 124-130
CrossRef74
T. Breidthardt, M. Noveanu, M. Potocki, T. Reichlin, P. Egli, S. Hartwiger, T. Socrates, E. Gayat, M. Christ, A. Mebazaa, C. Mueller. (2010) Impact of a high-dose nitrate strategy on cardiac stress in acute heart failure: a pilot study. Journal of Internal Medicine 267:3, 322-330
CrossRef75
Thomas J. Urban. (2010) Race, Ethnicity, Ancestry, and Pharmacogenetics. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:2, 133-139
CrossRef76
Y Li, Y Saito, K Kuwahara, X Rong, I Kishimoto, M Harada, M Horiuchi, M Murray, K Nakao. (2010) Vasodilator therapy with hydralazine induces angiotensin AT2 receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A. British Journal of Pharmacology 159:5, 1133-1142
CrossRef77
Jennifer NA Silva, Charles E Canter. (2010) Current management of pediatric dilated cardiomyopathy. Current Opinion in Cardiology 25:2, 80-87
CrossRef78
Maria Gabriella Matera, Eugenio Martuscelli, Mario Cazzola. (2010) Pharmacological modulation of β-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. Pulmonary Pharmacology & Therapeutics 23:1, 1-8
CrossRef79
Charles R Salters, Alison L Bailey, Thomas F Whayne. (2010) Current treatment of heart failure in the USA. Expert Review of Cardiovascular Therapy 8:2, 279-290
CrossRef80
David R. Williams, Selina A. Mohammed, Jacinta Leavell, Chiquita Collins. (2010) Race, socioeconomic status, and health: Complexities, ongoing challenges, and research opportunities. Annals of the New York Academy of Sciences 1186:1, 69-101
CrossRef81
McMurray, John J.V., . (2010) Systolic Heart Failure. New England Journal of Medicine 362:3, 228-238
Full Text82
Liewei Wang. (2010) Pharmacogenomics: a systems approach. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 2:1, 3-22
CrossRef83
Clyde W. Yancy, Gregg C. Fonarow, Nancy M. Albert, Anne B. Curtis, Wendy Gattis Stough, Mihai Gheorghiade, J. Thomas Heywood, Mark L. McBride, Mandeep R. Mehra, Christopher M. O'Connor, Dwight Reynolds, Mary Norine Walsh. (2010) Adherence to Guideline-Recommended Adjunctive Heart Failure Therapies Among Outpatient Cardiology Practices (Findings from IMPROVE HF). The American Journal of Cardiology 105:2, 255-260
CrossRef84
Periaswamy Velavan, Nasrin K. Khan, Kevin Goode, Alan S. Rigby, Poay H. Loh, Michel Komajda, Ferenc Follath, Karl Swedberg, Hugo Madeira, John G.F. Cleland. (2010) Predictors of short term mortality in heart failure — Insights from the Euro Heart Failure survey. International Journal of Cardiology 138:1, 63-69
CrossRef85
Matthias Oelze, Swenja Schuhmacher, Andreas Daiber. (2010) Organic Nitrates and Nitrate Resistance in Diabetes: The Role of Vascular Dysfunction and Oxidative Stress with Emphasis on Antioxidant Properties of Pentaerithrityl Tetranitrate. Experimental Diabetes Research 2010, 1-13
CrossRef86
Edoardo Camenzind, William Wijns, Laura Mauri, Eric Boersma, Keyur Parikh, Volkhard Kurowski, Runlin Gao, Christoph Bode, John P. Greenwood, Anthony Gershlick, William O'Neill, Patrick W. Serruys, Brenda Jorissen, P. Gabriel Steg. (2009) Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): Randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. American Heart Journal 158:6, 902-909.e5
CrossRef87
Ali El-Armouche, Thomas Eschenhagen. (2009) β-Adrenergic stimulation and myocardial function in the failing heart. Heart Failure Reviews 14:4, 225-241
CrossRef88
Peter Carson, S. William Tam, Jalal K. Ghali, W. Tad Archambault, Anne Taylor, Jay N. Cohn, Virginia M. Braman, Manuel Worcel, Inder S. Anand. (2009) Relationship of Quality of Life Scores With Baseline Characteristics and Outcomes in the African-American Heart Failure Trial. Journal of Cardiac Failure 15:10, 835-842
CrossRef89
Benjamin J Epstein, Steven M Smith, Rushab Choksi. (2009) Recent changes in the landscape of combination RAS blockade. Expert Review of Cardiovascular Therapy 7:11, 1373-1384
CrossRef90
R. Preston Mason, Ruslan Kubant, Robert F. Jacob, Peter Malinski, Xiaoyan Huang, Febee R. Louka, Jan Borowiec, Yoshiko Mizuno, Tadeusz Malinski. (2009) Loss of Arterial and Renal Nitric Oxide Bioavailability in Hypertensive Rats With Diabetes: Effect of β-Blockers. American Journal of Hypertension 22:11, 1160-1166
CrossRef91
C. Göggelmann, A. Filusch, F.J. Meyer. (2009) Pulmonale Effekte kardialer Therapie und vice versa. Der Pneumologe 6:6, 399-404
CrossRef92
Sean R. Wilson, Michael M. Givertz, Garrick C. Stewart, Gilbert H. Mudge. (2009) Ventricular Assist Devices. Journal of the American College of Cardiology 54:18, 1647-1659
CrossRef93
Tommaso Gori, Thomas Münzel. (2009) Symptomatic and hemodynamic benefit of pentaerythrityl tetranitrate and hydralazine in a case of congestive heart failure. Clinical Research in Cardiology 98:10, 677-679
CrossRef94
Luca Ansaloni, Fausto Catena, Antonio Daniele Pinna. (2009) What is the Meaning of “Race Based Surgery”?. Annals of Surgery 250:4, 652
CrossRef95
Brenda S. Thompson. (2009) Sudden Cardiac Death and Heart Failure. AACN Advanced Critical Care 20:4, 356-365
CrossRef96
R. Bhopal. (2009) Medicine and public health in a multiethnic world. Journal of Public Health 31:3, 315-321
CrossRef97
Matthew W. Foster, Douglas T. Hess, Jonathan S. Stamler. (2009) Protein S-nitrosylation in health and disease: a current perspective. Trends in Molecular Medicine 15:9, 391-404
CrossRef98
Girish Dwivedi, D Gareth Beevers. (2009) Hypertension in ethnic groups: epidemiological and clinical perspectives. Expert Review of Cardiovascular Therapy 7:8, 955-963
CrossRef99
Mohammad N. Jameel, Jianyi Zhang. (2009) Heart Failure Management: The Present and the Future. Antioxidants & Redox Signaling 11:8, 1989-2010
CrossRef100
Clyde W. Yancy, Arthur Feldman. (2009) Isosorbide Dinitrate and Hydralazine as Therapy for African Americans with Heart Failure; a Failed Paradigm?. Clinical and Translational Science 2:4, 309-311
CrossRef101
Xiaohuan Gao, Debabrata Saha, Payal Kapur, Thomas Anthony, Edward H. Livingston, Sergio Huerta. (2009) Radiosensitization of HT-29 cells and xenografts by the nitric oxide donor DETANONOate. Journal of Surgical Oncology 100:2, 149-158
CrossRef102
Randy Wexler, Adam Pleister, David Feldman. (2009) Sociology meets genetics: Sociogenetic implications for future management of hypertension and heart failure. Current Treatment Options in Cardiovascular Medicine 11:4, 305-315
CrossRef103
Arnon Blum. (2009) Treating Heart Failure With Sildenafil. Congestive Heart Failure 15:4, 181-185
CrossRef104
K. K. Gordon Lan, David DeMets. (2009) Further Comments on the Alpha Spending Function. Statistics in Biosciences
CrossRef105
Michael R. MacDonald, Mark C. Petrie, Miles Fisher, John J. V. McMurray. (2009) Pharmacologic management of patients with both heart failure and diabetes. Current Heart Failure Reports 6:2, 126-132
CrossRef106
Vinay Thohan, Shomeet Patel. (2009) The challenges associated with current clinical trials for diastolic heart failure. Current Opinion in Cardiology 24:3, 230-238
CrossRef107
K. K. Gordon Lan, David DeMets. (2009) Further Comments on the Alpha-Spending Function. Statistics in Biosciences 1:1, 95-111
CrossRef108
Keith C. Ferdinand, Daphne P. Ferdinand. (2009) Cardiovascular disease disparities: Racial/ethnic factors and potential solutions. Current Cardiovascular Risk Reports 3:3, 187-193
CrossRef109
M. J. Thomson, M. P. Frenneaux, J. C. Kaski. (2009) Antioxidant treatment for heart failure: friend or foe?. QJM 102:5, 305-310
CrossRef110
Jay Cohn, John G.F. Cleland, Jacobus Lubsen, Jeffrey S. Borer, Philippe Gabriel Steg, Michael Perelman, Faiez Zannad. (2009) Unconventional End Points in Cardiovascular Clinical Trials: Should We Be Moving Away From Morbidity and Mortality?. Journal of Cardiac Failure 15:3, 199-205
CrossRef111
Saraswathy Manickavasagam, Ramanna Merla, Michael M Koerner, Ken Fujise, Sanjay Kunapuli, Salvatore Rosanio, Alejandro Barbagelata. (2009) Management of hypertension in chronic heart failure. Expert Review of Cardiovascular Therapy 7:4, 423-433
CrossRef112
Wilfried Mullens, Zuheir Abrahams, Gary S. Francis, George Sokos, Randall C. Starling, James B. Young, David O. Taylor, W.H. Wilson Tang. (2009) Usefulness of Isosorbide Dinitrate and Hydralazine as Add-on Therapy in Patients Discharged for Advanced Decompensated Heart Failure. The American Journal of Cardiology 103:8, 1113-1119
CrossRef113
Sharon Ann Hunt, William T. Abraham, Marshall H. Chin, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Mariell Jessup, Marvin A. Konstam, Donna M. Mancini, Keith Michl, John A. Oates, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy. (2009) 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology 53:15, e1-e90
CrossRef114
Madhumathi Rao, V.S. Balakrishnan. (2009) The Genetic Basis of Kidney Disease Risk in African Americans: MYH9 as a New Candidate Gene. American Journal of Kidney Diseases 53:4, 579-583
CrossRef115
Clyde W. Yancy, Gregg C. Fonarow, Nancy M. Albert, Anne B. Curtis, Wendy Gattis Stough, Mihai Gheorghiade, J. Thomas Heywood, Mark L. McBride, Mandeep R. Mehra, Christopher M. O'Connor, Dwight Reynolds, Mary Norine Walsh. (2009) Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: Findings from IMPROVE HF. American Heart Journal 157:4, 754-762.e2
CrossRef116
Dennis M. McNamara, S. William Tam, Michael L. Sabolinski, Page Tobelmann, Karen Janosko, Lakshmi Venkitachalam, Elizabeth Ofili, Clyde Yancy, Arthur M. Feldman, Jalal K Ghali, Anne L. Taylor, Jay N. Cohn, Manuel Worcel. (2009) Endothelial Nitric Oxide Synthase (NOS3) Polymorphisms in African Americans With Heart Failure: Results From the A-HeFT Trial. Journal of Cardiac Failure 15:3, 191-198
CrossRef117
Sergio Huerta, Guillermina Baay-Guzman, Cesar R. Gonzalez-Bonilla, Edward H. Livingston, Sara Huerta-Yepez, Benjamin Bonavida. (2009) In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF. Nitric Oxide 20:3, 182-194
CrossRef118
Jalal K Ghali. (2009) Sex, race and ethnicity: providing quality care for elderly patients hospitalized with heart failure. Aging Health 5:2, 171-176
CrossRef119
H.J. Dargie. (2009) Current controversies in drug use. European Journal of Heart Failure Supplements 8:Supplement 1, i15-i20
CrossRef120
Mariell Jessup, William T. Abraham, Donald E. Casey, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Marvin A. Konstam, Donna M. Mancini, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy. (2009) 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology 53:15, 1343-1382
CrossRef121
Henry Krum, William T Abraham. (2009) Heart failure. The Lancet 373:9667, 941-955
CrossRef122
Stephen Joel Coons. (2009) Have we witnessed the rise and fall of race-specific drugs?. Clinical Therapeutics 31:3, 620-622
CrossRef123
Wayne L. Miller, Hadi N. Skouri. (2009) Chronic Systolic Heart Failure, Guideline-Directed Medical Therapy, and Systemic Hypotension—Less Pressure but Maybe More Risk (Does This Clinical Scenario Need More Discussion?). Journal of Cardiac Failure 15:2, 101-107
CrossRef124
Jamshid Shirani, Vasken Dilsizian. (2009) Molecular imaging targets of cardiac remodeling. Current Cardiology Reports 11:2, 148-154
CrossRef125
Karl E. Hammermeister, Diane Fairclough, Caroline Bublitz Emsermann, Richard Hamman, Michael Ho, Stephanie Phibbs, Mary Plomondon, Robert Valuck, David West, John F. Steiner. (2009) Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure. Clinical Therapeutics 31:3, 632-643
CrossRef126
Hamayun Nawaz, Allan S Brett. (2009) Mentioning race at the beginning of clinical case presentations: a survey of US medical schools. Medical Education 43:2, 146-154
CrossRef127
David C. Sane, Nathan P. Streer, John Owen. (2009) Myocardial necrosis in patients with thrombotic thrombocytopenic purpura: pathophysiology and rationale for specific therapy. European Journal of Haematology 82:2, 83-92
CrossRef128
Pawan D. Patel, Jose L. Velazquez, Rohit R. Arora. (2009) Endothelial dysfunction in African-Americans. International Journal of Cardiology 132:2, 157-172
CrossRef129
Cynthia A Jackevicius, Robert L Page, Sheryl Chow, Steven P Dunn, Craig R Lee, Tien M. H Ng, Jo E Rodgers, Orly Vardeny, Barbara S Wiggins, Mark A Munger. (2009) High-Impact Articles Related to the Management of Heart Failure: 2008 Update. Pharmacotherapy 29:1, 82-120
CrossRef130
AD Johnson, Y Gong, D Wang, TY Langaee, J Shin, RM Cooper-DeHoff, NJ Schork, P Binkley, CJ Pepine, JA Johnson, W Sadee. (2009) Promoter Polymorphisms in ACE (Angiotensin I–Converting Enzyme) Associated With Clinical Outcomes in Hypertension. Clinical Pharmacology & Therapeutics 85:1, 36-44
CrossRef131
Jon W. Schrock, Charles L. Emerman. (2009) Observation Unit Management of Acute Decompensated Heart Failure. Heart Failure Clinics 5:1, 85-100
CrossRef132
Juan M. Aranda, James W. Johnson, Jamie B. Conti. (2009) Current trends in heart failure readmission rates: analysis of medicare data. Clinical Cardiology 32:1, 47-52
CrossRef133
J. Paul Rocchiccioli, John J.V. McMurray. (2008) Medical management of advanced heart failure. Progress in Palliative Care 16:5, 229-240
CrossRef134
(2008) Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008). Revista Española de Cardiología 61:12, 1329.e1-1329.e70
CrossRef135
Keith C Ferdinand, Daphne P Ferdinand. (2008) Race-based therapy for hypertension: possible benefits and potential pitfalls. Expert Review of Cardiovascular Therapy 6:10, 1357-1366
CrossRef136
Brian D. Lowes, Peter M. Buttrick. (2008) Genetic determinants of drug response in heart failure. Current Cardiovascular Risk Reports 2:6, 485-490
CrossRef137
Jalal K. Ghali, S. William Tam, Michael L. Sabolinski, Anne L. Taylor, Joann Lindenfeld, Jay N. Cohn, Manuel Worcel. (2008) Exploring the Potential Synergistic Action of Spironolactone on Nitric Oxide–Enhancing Therapy: Insights From the African-American Heart Failure Trial. Journal of Cardiac Failure 14:9, 718-723
CrossRef138
Jane L Yen-Revollo, J Todd Auman, Howard L McLeod. (2008) Race does not explain genetic heterogeneity in pharmacogenomic pathways. Pharmacogenomics 9:11, 1639-1645
CrossRef139
Michael Krohn, Alice Kleber, Gregor Schaffar, Ute Dechert, Jürgen Eck. (2008) Now we are talking sense! Functional approaches to novel nutraceuticals and cosmeceuticals. Biotechnology Journal 3:9-10, 1147-1156
CrossRef140
, K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, A. W. Hoes, A. Keren, A. Mebazaa, M. Nieminen, S. G. Priori, K. Swedberg, , A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S. D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J. L. Zamorano, , M. Tendera, A. Auricchio, J. Bax, M. Bohm, U. Corra, P. della Bella, P. M. Elliott, F. Follath, M. Gheorghiade, Y. Hasin, A. Hernborg, T. Jaarsma, M. Komajda, R. Kornowski, M. Piepoli, B. Prendergast, L. Tavazzi, J.-L. Vachiery, F. W. A. Verheugt, J. L. Zamorano, F. Zannad. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal 29:19, 2388-2442
CrossRef141
Marielle Scherrer-Crosbie, Helène B. Thibault. (2008) Echocardiography in Translational Research: Of Mice and Men. Journal of the American Society of Echocardiography 21:10, 1083-1092
CrossRef142
Ron Blankstein, George L. Bakris. (2008) Changes in Kidney Function Following Heart Failure Treatment: Focus on Renin-Angiotensin System Blockade. Heart Failure Clinics 4:4, 425-438
CrossRef143
Theresa A McDonagh. (2008) Challenges in advanced chronic heart failure: drug therapy. Future Cardiology 4:5, 517-525
CrossRef144
Keith C. Ferdinand. (2008) Fixed-Dose Isosorbide Dinitrate-Hydralazine: Race-Based Cardiovascular Medicine Benefit or Mirage?. The Journal of Law, Medicine & Ethics 36:3, 458-463
CrossRef145
Lilian Grigorian-Shamagian, Jose Ramon Gonzalez-JuAnatey, Rafael Vazquez, Juan Cinca, Antoni Bayes-Genis, Domingo Pascual, Carlos Fernandez-Palomeque, Alfredo Bardaji, Jesus Almendral, Vicente Nieto, Carlos Macaya, Ricardo Pavon Jimenez, Antoni Bayes de Luna. (2008) Association of Blood Pressure and Its Evolving Changes With the Survival of Patients With Heart Failure. Journal of Cardiac Failure 14:7, 561-568
CrossRef146
Ali Jawa, Senthil Nachimuthu, Merri Pendergrass, Sunil Asnani, Vivian Fonseca. (2008) Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. Journal of Diabetes and its Complications 22:5, 303-308
CrossRef147
Gregory Michael Dorr, David S. Jones. (2008) Introduction: Facts and Fictions: BiDil and the Resurgence of Racial Medicine. The Journal of Law, Medicine & Ethics 36:3, 443-448
CrossRef148
Robert A. Phillips, Vivian Fonseca, Richard E. Katholi, Janet B. McGill, Franz H. Messerli, David S.H. Bell, Philip Raskin, Jackson T. Wright Jr, Malini Iyengar, Karen M. Anderson, Mary Ann Lukas, George L. Bakris, . (2008) Demographic Analyses of the Effects of Carvedilol vs Metoprolol on Glycemic Control and Insulin Sensitivity in Patients With Type 2 Diabetes and Hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) Study. Journal of the CardioMetabolic Syndrome 3:4, 211-217
CrossRef149
George T. H. Ellison, Jay S. Kaufman, Rosemary F. Head, Paul A. Martin, Jonathan D. Kahn. (2008) Flaws in the U.S. Food and Drug Administration's Rationale for Supporting the Development and Approval of BiDil as a Treatment for Heart Failure Only in Black Patients. The Journal of Law, Medicine & Ethics 36:3, 449-457
CrossRef150
Kathryn L. Rice, Inge Leimer, Steven Kesten, Dennis E. Niewoehner. (2008) Responses to tiotropium in African-American and Caucasian patients with chronic obstructive pulmonary disease. Translational Research 152:2, 88-94
CrossRef151
Michael Kindermann, M. Bohm. (2008) Aktuelle konservative Therapie der chronischen Herzinsuffizienz. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 22:4, 184-196
CrossRef152
Jamshid Shirani, Vasken Dilsizian. (2008) Imaging left ventricular remodeling: targeting the neurohumoral axis. Nature Clinical Practice Cardiovascular Medicine 5, S57-S62
CrossRef153
Ameen F. Person, Cam Patterson. (2008) Therapeutic options for premature coronary artery disease. Current Treatment Options in Cardiovascular Medicine 10:4, 294-303
CrossRef154
Marc A. Simon, John Watson, J. Timothy Baldwin, William R. Wagner, Harvey S. Borovetz. (2008) Current and Future Considerations in the Use of Mechanical Circulatory Support Devices*. Annual Review of Biomedical Engineering 10:1, 59-84
CrossRef155
Clyde W. Yancy. (2008) Race-based therapeutics. Current Hypertension Reports 10:4, 276-285
CrossRef156
David Feldman, Doron M. Menachemi, William T. Abraham, Randell K. Wexler. (2008) Management Strategies for Stage‐D Patients with Acute Heart Failure. Clinical Cardiology 31:7, 297-301
CrossRef157
Wilfried Mullens, Zuheir Abrahams, Gary S. Francis, Hadi N. Skouri, Randall C. Starling, James B. Young, David O. Taylor, W.H. Wilson Tang. (2008) Sodium Nitroprusside for Advanced Low-Output Heart Failure. Journal of the American College of Cardiology 52:3, 200-207
CrossRef158
Werner Schmid, Alexander Lee, Jinhi Son, Elisabeth Koller, Ivo Volf. (2008) Hypochlorite-oxidized low density lipoproteins reduce production and bioavailability of nitric oxide in RAW 264.7 macrophages by distinct mechanisms. Life Sciences 83:1-2, 50-58
CrossRef159
Nicholas B Norgard, Jennifer E Stark. (2008) Pharmacotherapy for Heart Failure with Left Ventricular Dysfunction: Beyond Angiotensin-Converting Enzyme Inhibitors and β-Blockers. Pharmacotherapy 28:7, 920-931
CrossRef160
Tommaso Gori, John D. Parker. (2008) Nitrate-Induced Toxicity and Preconditioning. Journal of the American College of Cardiology 52:4, 251-254
CrossRef161
Giovanni Gambassi, Syed Abbas Agha, Xuemei Sui, Clyde W. Yancy, Javed Butler, Grigorios Giamouzis, Thomas E. Love, Ali Ahmed. (2008) Race and the Natural History of Chronic Heart Failure: A Propensity-Matched Study. Journal of Cardiac Failure 14:5, 373-378
CrossRef162
B Séguin, B Hardy, P A Singer, A S Daar. (2008) Bidil: recontextualizing the race debate. The Pharmacogenomics Journal 8:3, 169-173
CrossRef163
Joachim H. Ix, Matthew A. Allison, Julie O. Denenberg, Mary Cushman, Michael H. Criqui. (2008) Novel Cardiovascular Risk Factors Do Not Completely Explain the Higher Prevalence of Peripheral Arterial Disease Among African Americans. Journal of the American College of Cardiology 51:24, 2347-2354
CrossRef164
Brian D. Lowes, Peter M. Buttrick. (2008) Genetic determinants of drug response in heart failure. Current Cardiology Reports 10:3, 176-181
CrossRef165
Tamara B. Horwich, Gregg C. Fonarow. (2008) Heart failure in African Americans: Earlier onset, different etiologies, and poorer prognosis. Current Cardiovascular Risk Reports 2:3, 198-202
CrossRef166
Andreas Brieke, Joseph Cleveland, JoAnn Lindenfeld. (2008) Mechanical support in acute and chronic heart failure. Current Cardiology Reports 10:3, 168-175
CrossRef167
David W. Markham, Daniel L. Dries, Louise P. King, David Leonard, Clyde W. Yancy, Ronald M. Peshock, DuWayne Willett, Richard S. Cooper, Mark H. Drazner. (2008) Blacks and whites have a similar prevalence of reduced left ventricular ejection fraction in the general population: The Dallas Heart Study (DHS). American Heart Journal 155:5, 876-882
CrossRef168
L. Michael Prisant, Kevin L. Thomas, Eldrin F. Lewis, Zhen Huang, Gary S. Francis, W. Douglas Weaver, Marc A. Pfeffer, John J.V. McMurray, Robert M. Califf, Eric J. Velazquez. (2008) Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both. Journal of the American College of Cardiology 51:19, 1865-1871
CrossRef169
Dennis M McNamara. (2008) Emerging role of pharmacogenomics in heart failure. Current Opinion in Cardiology 23:3, 261-268
CrossRef170
Thomas Dieterle, Matthias Pfisterer, Hanspeter Brunner-La Rocca. (2008) Heart failure in the elderly. Aging Health 4:2, 137-155
CrossRef171
Jalal K Ghali, JoAnn Lindenfeld. (2008) Sex differences in response to chronic heart failure therapies. Expert Review of Cardiovascular Therapy 6:4, 555-565
CrossRef172
Clyde W. Yancy, William T. Abraham, Nancy M. Albert, Robert Clare, Wendy Gattis Stough, Mihai Gheorghiade, Barry H. Greenberg, Christopher M. O'Connor, Lilin She, Jie Lena Sun, James B. Young, Gregg C. Fonarow. (2008) Quality of Care of and Outcomes for African Americans Hospitalized With Heart Failure. Journal of the American College of Cardiology 51:17, 1675-1684
CrossRef173
Jay S. Kaufman. (2008) Epidemiologic analysis of racial/ethnic disparities: A rejoinder to Frank and Exner. Social Science & Medicine 66:8, 1678-1680
CrossRef174
Derek V. Exner, Jay N. Cohn. (2008) Arguments prove nothing unless verified. A commentary on Kaufman's “Epidemiologic analysis of racial/ethnic disparities: Some fundamental issues and a cautionary example”. Social Science & Medicine 66:8, 1675-1677
CrossRef175
Erin Farrell, Jonathan Usuka. (2008) Pharmacogenomics and drug development: the impact of US FDA postapproval tracking on clinical pharmacology. Personalized Medicine 5:2, 133-139
CrossRef176
Robert C. Bourge, William T. Abraham, Philip B. Adamson, Mark F. Aaron, Juan M. Aranda, Anthony Magalski, Michael R. Zile, Andrew L. Smith, Frank W. Smart, Mark A. O’Shaughnessy, Mariell L. Jessup, Brandon Sparks, David L. Naftel, Lynne Warner Stevenson. (2008) Randomized Controlled Trial of an Implantable Continuous Hemodynamic Monitor in Patients With Advanced Heart Failure. Journal of the American College of Cardiology 51:11, 1073-1079
CrossRef177
Nadine Gauthier, Anjali H Anselm, Haissam Haddad. (2008) New therapies in acute decompensated heart failure. Current Opinion in Cardiology 23:2, 134-140
CrossRef178
John Lynch, Jennifer Bevan, Paul Achter, Tina Harris, Celeste M. Condit. (2008) A preliminary study of how multiple exposures to messages about genetics impact on lay attitudes towards racial and genetic discrimination. New Genetics and Society 27:1, 43-56
CrossRef179
James O. Mudd, David A. Kass. (2008) Tackling heart failure in the twenty-first century. Nature 451:7181, 919-928
CrossRef180
Daniel E. Forman, Ronald A. Cohen, Karin F. Hoth, Andreana P. Haley, Athena Poppas, David J. Moser, John Gunstad, Robert H. Paul, Angela L. Jefferson, David F. Tate, Makoto Ono, Nicole Wake, Marie Gerhard-Herman. (2008) Vascular health and cognitive function in older adults with cardiovascular disease. Artery Research 2:1, 35-43
CrossRef181
Paul J. Hauptman. (2008) Medication adherence in heart failure. Heart Failure Reviews 13:1, 99-106
CrossRef182
Dalane W. Kitzman, Jerome L. Fleg. 2008. Heart Failure. , 542-576.
CrossRef183
Gian M. Novaro, Craig R. Asher, Deepak L. Bhatt, David J. Moliterno, Robert A. Harrington, A. Michael Lincoff, L. Kristin Newby, James E. Tcheng, Amy P. Hsu, Sergio L. Pinski. (2008) Meta-Analysis Comparing Reported Frequency of Atrial Fibrillation After Acute Coronary Syndromes in Asians Versus Whites. The American Journal of Cardiology 101:4, 506-509
CrossRef184
Suzanne B. Brown, Richard P. Shannon. (2008) Improving Medication Compliance in Patients With Heart Failure. The American Journal of Cardiology 101:2, 274-277
CrossRef185
Darcy A. Lamb, David F. Blackburn, Anne M. PausJenssen, William M. Semchuk, Patrick Robertson. (2008) Heart failure: Back to basics for pharmacists. Canadian Pharmacists Journal 141:1, 48-57
CrossRef186
Shakil Aslam. (2008) Cardiovascular disease in dialysis patients: do some antihypertensive drugs have specific antioxidant effects or is it just blood pressure reduction? Does antioxidant treatment reduce the risk for cardiovascular disease?. Current Opinion in Nephrology and Hypertension 17:1, 99-105
CrossRef187
Arthur L. Riba. (2008) Evidence-Based Performance and Quality Improvement in the Acute Cardiac Care Setting. Critical Care Clinics 24:1, 201-229
CrossRef188
Masoor Kamalesh. (2007) Heart Failure in Diabetes and Related Conditions. Journal of Cardiac Failure 13:10, 861-873
CrossRef189
Kiran K. Khush, Sanjiv J. Shah, Bryan Ristow, Teresa De Marco, Mary A. Whooley, Nelson B. Schiller. (2007) Association of African American Race with Elevated Pulmonary Artery Diastolic Pressure: Data from the Heart and Soul Study. Journal of the American Society of Echocardiography 20:11, 1307-1313
CrossRef190
Oberdan Parodi, Renata De Maria, Elena Roubina. (2007) Redox state, oxidative stress and endothelial dysfunction in heart failure: the puzzle of nitrate–thiol interaction. Journal of Cardiovascular Medicine 8:10, 765-774
CrossRef191
Wilbert S. Aronow. (2007) Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly. Heart Failure Clinics 3:4, 423-436
CrossRef192
Albertino Damasceno, Gad Cotter, Anastase Dzudie, Karen Sliwa, Bongani M. Mayosi. (2007) Heart Failure in Sub-Saharan Africa: Time for Action. Journal of the American College of Cardiology 50:17, 1688-1693
CrossRef193
Luis E. Rohde, Dora V. Palombini, Carisi A. Polanczyk, Lívia A. Goldraich, Nadine Clausell. (2007) A Hemodynamically Oriented Echocardiography-Based Strategy in the Treatment of Congestive Heart Failure. Journal of Cardiac Failure 13:8, 618-625
CrossRef194
David Rosen, Matthew V. Decaro, Mark G. Graham. (2007) Evidence-based Treatment of Chronic Heart Failure. Comprehensive Therapy 33:1, 2-17
CrossRef195
Barbara J. Messinger-Rapport, John E. Morley, David R. Thomas, Julie K. Gammack. (2007) Intensive Session: New Approaches to Medical Issues in Long-Term Care. Journal of the American Medical Directors Association 8:7, 421-433
CrossRef196
Steven W. Werns. (2007) Are nitrates safe in patients who use sildenafil? Maybe*. Critical Care Medicine 35:8, 1988-1990
CrossRef197
Jay N. Cohn. (2007) Myocardial Structural Effects of Aldosterone Receptor Antagonism in Heart Failure. Journal of the American College of Cardiology 50:7, 597-599
CrossRef198
Clyde W. Yancy, Jalal K. Ghali, Virginia M. Braman, Michael L. Sabolinski, Manuel Worcel, W. Tad Archambault, Joseph A. Franciosa. (2007) Evidence for the Continued Safety and Tolerability of Fixed-Dose Isosorbide Dinitrate/Hydralazine in Patients With Chronic Heart Failure (the Extension to African-American Heart Failure Trial). The American Journal of Cardiology 100:4, 684-689
CrossRef199
Udho Thadani, Toni L Ripley. (2007) Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction. Expert Opinion on Drug Safety 6:4, 385-396
CrossRef200
James F. Jackson, Asher Kornbluth. (2007) Do Black and Hispanic Americans With Inflammatory Bowel Disease (IBD) Receive Inferior Care Compared With White Americans? Uneasy Questions and Speculations. The American Journal of Gastroenterology 102:7, 1343-1349
CrossRef201
Steve Tsai, Marc Klapholz. (2007) Tips and tricks on outpatient initiation and uptitration of beta-blockade in heart failure. Current Heart Failure Reports 4:2, 110-116
CrossRef202
Keith C. Ferdinand, Annemarie M. Armani. (2007) The Management of Hypertension in African Americans. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 6:2, 67-71
CrossRef203
Jay N. Cohn, S. William Tam, Inder S. Anand, Anne L. Taylor, Michael L. Sabolinski, Manuel Worcel. (2007) Isosorbide Dinitrate and Hydralazine in a Fixed-Dose Combination Produces Further Regression of Left Ventricular Remodeling in a Well-Treated Black Population With Heart Failure: Results From A-HeFT. Journal of Cardiac Failure 13:5, 331-339
CrossRef204
G. William Dec. (2007) Management of Acute Decompensated Heart Failure. Current Problems in Cardiology 32:6, 321-366
CrossRef205
Larisa H Cavallari, Kathryn M Momary, Vicki L Groo, Marlos A. G Viana, Joseph R Camp, Thomas D Stamos. (2007) Association of β-Blocker Dose with Serum Procollagen Concentrations and Cardiac Response to Spironolactone in Patients with Heart Failure. Pharmacotherapy 27:6, 801-812
CrossRef206
Clyde W. Yancy. (2007) Race-based therapeutics. Current Cardiovascular Risk Reports 1:2, 108-117
CrossRef207
Evian Gordon. (2007) Integrating genomics and neuromarkers for the era of brain-related personalized medicine. Personalized Medicine 4:2, 201-215
CrossRef208
Gautam R. Shroff, Anne L. Taylor, Monica Colvin-Adams. (2007) Race-related differences in heart failure therapies: Simply black and white or shades of grey?. Current Cardiology Reports 9:3, 178-181
CrossRef209
Keith C. Ferdinand, Annemarie Armani. (2007) Combating racial and ethnic disparities in cardiovascular disease: What is being done?. Current Cardiovascular Risk Reports 1:2, 124-132
CrossRef210
Alain Li Wan Po. (2007) Personalised medicine: who is an Asian?. The Lancet 369:9575, 1770-1771
CrossRef211
James O Mudd, David A Kass. (2007) Reversing chronic remodeling in heart failure. Expert Review of Cardiovascular Therapy 5:3, 585-598
CrossRef212
Kenneth Y. Tsai, Hensin Tsao. (2007) Primer on the human genome. Journal of the American Academy of Dermatology 56:5, 719-735
CrossRef213
Mark E Dunlap. (2007) New Studies Influencing Treatment of Heart Failure: 2006 Update. Pharmacotherapy 27:4 Part 2, 3S-11S
CrossRef214
Marjorie K. Mau, Margaret R. West, Nawar M. Shara, Jimmy T. Efird, Kavitha Alimineti, Erin Saito, Jared Sugihara, Roland Ng. (2007) Epidemiologic and clinical factors associated with Chronic Kidney Disease among Asian Americans and Native Hawaiians. Ethnicity & Health 12:2, 111-127
CrossRef215
Camille G. Frazier, Karen P. Alexander, L. Kristin Newby, Susan Anderson, Erik Iverson, Milton Packer, Jay Cohn, Sidney Goldstein, Pamela S. Douglas. (2007) Associations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction. Journal of the American College of Cardiology 49:13, 1450-1458
CrossRef216
Jalal K. Ghali. (2007) Hydralazine and Nitrates: Beyond Race and Ethnicity. Journal of Cardiac Failure 13:3, 238
CrossRef217
Carmen Dumaual, Xin Miao, Thomas M Daly, Carsten Bruckner, Reuben Njau, Dong-Jing Fu, Sandra Close-Kirkwood, Nancy Bauer, Nancy Watanabe, Paul Hardenbol, Richard D Hockett. (2007) Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix ® Targeted Genotyping System. Pharmacogenomics 8:3, 293-305
CrossRef218
Jennifer Listerman, Carrie Geisberg, Mary A. Nading, Joann Goring, Robert Huang, Javed Butler. (2007) Blunted Hemodynamic Response and Reduced Oxygen Delivery With Exercise in Anemic Heart Failure Patients With Systolic Dysfunction. Congestive Heart Failure 13:2, 71-77
CrossRef219
George R. Thomas, Jonathan M. DiFabio, Tommaso Gori, John D. Parker. (2007) Once Daily Therapy With Isosorbide-5-Mononitrate Causes Endothelial Dysfunction in Humans. Journal of the American College of Cardiology 49:12, 1289-1295
CrossRef220
Yohannes Gebreegziabher, Amgad N Makaryus, John N Makaryus, Samy I McFarlane. (2007) Heart failure: metabolic derangements and therapeutic rationale. Expert Review of Cardiovascular Therapy 5:2, 331-343
CrossRef221
Ferdinand Keith C. (2007) New Antihypertensive Agents: Will They Work in Blacks?. The Journal of Clinical Hypertension 9:3, 165-167
CrossRef222
Krista M. Dale, Craig I. Coleman, Sachin A. Shah, Aarti A. Patel, Jeffrey Kluger, C. Michael White. (2007) Impact of gender on statin efficacy. Current Medical Research and Opinion 23:3, 565-574
CrossRef223
Elizabeth A. Liberts, Scott R. Willoughby, Jennifer A. Kennedy, John D. Horowitz. (2007) Effects of perhexiline and nitroglycerin on vascular, neutrophil and platelet function in patients with stable angina pectoris. European Journal of Pharmacology 560:1, 49-55
CrossRef224
Roy H. Perlis. (2007) Pharmacogenetic Studies of Antidepressant Response: How Far from the Clinic?. Psychiatric Clinics of North America 30:1, 125-138
CrossRef225
Fadia T. Shaya, Confidence M. Gbarayor, Huiwen Keri Yang, Marriette Agyeman-Duah, Elijah Saunders. (2007) A perspective on African American participation in clinical trials. Contemporary Clinical Trials 28:2, 213-217
CrossRef226
John M Flack. (2007) Editorial commentary on fixed combination isosorbide dinitrate/hydralazine for nitric-oxide-enhancing therapy in heart failure. Expert Opinion on Pharmacotherapy 8:3, 275-277
CrossRef227
Athanase D Protogerou, Theodore G Papaioannou, Jacques Blacher, Christos M Papamichael, John P Lekakis, Michel E Safar. (2007) Central blood pressures: do we need them in the management of cardiovascular disease? Is it a feasible therapeutic target?. Journal of Hypertension 25:2, 265-272
CrossRef228
Troy Duster. (2007) Medicalisation of race. The Lancet 369:9562, 702-704
CrossRef229
Wilbert S. Aronow. (2007) Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly. Clinics in Geriatric Medicine 23:1, 61-81
CrossRef230
D Ghosh, M A Skinner, W A Laing. (2007) Pharmacogenomics and nutrigenomics: synergies and differences. European Journal of Clinical Nutrition
CrossRef231
Gregor Leibundgut, Matthias Pfisterer, Hans-Peter Brunner-La Rocca. (2007) Drug Treatment of Chronic Heart Failure in the Elderly. Drugs & Aging 24:12, 991-1006
CrossRef232
Marc A. Pfeffer. (2007) Blood Pressure in Heart Failure. Journal of the American College of Cardiology 49:1, 40-42
CrossRef233
T. Münzel, F. Post. (2007) Nitratbehandlung. Clinical Research in Cardiology Supplements 2:1, 31-42
CrossRef234
Melinda S. Carmody, Joe R. Anderson. (2007) BiDil (Isosorbide Dinitrate and Hydralazine). Cardiology in Review 15:1, 46-53
CrossRef235
Jalal K Ghali, S William Tam, Keith C Ferdinand, JoAnn Lindenfeld, Michael L Sabolinski, Anne L Taylor, Manuel Worcel, Charles L Curry, Jay N Cohn. (2007) Effects of ACE Inhibitors or β-Blockers in Patients Treated with the Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine in the African-American Heart Failure Trial. American Journal of Cardiovascular Drugs 7:5, 373-380
CrossRef236
S William Tam, Michael L Sabolinski, Manuel Worcel, Milton Packer, Jay N Cohn. (2007) Lack of Bioequivalence between Different Formulations of Isosorbide??Dinitrate and Hydralazine and??the??Fixed-Dose Combination of??Isosorbide Dinitrate/Hydralazine. Clinical Pharmacokinetics 46:10, 885-895
CrossRef237
Eman Hamad, Paul J Mather, Siva Srinivasan, Sharon Rubin, David J Whellan, Arthur M Feldman. (2007) Pharmacologic Therapy of Chronic Heart Failure. American Journal of Cardiovascular Drugs 7:4, 235-248
CrossRef238
Inder S. Anand, S. William Tam, Thomas S. Rector, Anne L. Taylor, Michael L. Sabolinski, W. Tad Archambault, Kirkwood F. Adams, Adeoye Y. Olukotun, Manuel Worcel, Jay N. Cohn. (2007) Influence of Blood Pressure on the Effectiveness of a Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine in the African-American Heart Failure Trial. Journal of the American College of Cardiology 49:1, 32-39
CrossRef239
William T. Abraham, Barry M. Massie, Mary Ann Lukas, Sandra R. Lottes, Jeanenne J. Nelson, Michael B. Fowler, Barry Greenberg, Edward M. Gilbert, Joseph A. Franciosa. (2007) Tolerability, Safety, and Efficacy of ?-Blockade in Black Patients With Heart Failure in the Community Setting: Insights From a Large Prospective ?-Blocker Registry. Congestive Heart Failure 13:1, 16-21
CrossRef240
John D. Harding, Mariell Jessup. (2006) New Directions in the Medical Management of Heart Failure. Seminars in Thoracic and Cardiovascular Surgery 17:4, 334-342
CrossRef241
Jill M. Gelow, James C. Fang. (2006) Update in the Approach to and Management of Heart Failure. Southern Medical Journal 99:12, 1346-1355
CrossRef242
Melvin R Echols, Clyde W Yancy. (2006) Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure. Vascular Health and Risk Management 2:4, 423-431
CrossRef243
Thomas D. Giles. (2006) Aspects of Nitric Oxide in Health and Disease: A Focus on Hypertension and Cardiovascular Disease. The Journal of Clinical Hypertension 8, 2-16
CrossRef244
Anne L. Taylor, JoAnn Lindenfeld, Susan Ziesche, Mary Norine Walsh, Judith E. Mitchell, Kirkwood Adams, S. William Tam, Elizabeth Ofili, Michael L. Sabolinski, Manuel Worcel, Jay N. Cohn. (2006) Outcomes by Gender in the African-American Heart Failure Trial. Journal of the American College of Cardiology 48:11, 2263-2267
CrossRef245
Joseph A Franciosa. (2006) Fixed combination isosorbide dinitrate–hydralazine for nitric-oxide-enhancing therapy in heart failure. Expert Opinion on Pharmacotherapy 7:18, 2521-2531
CrossRef246
R. Preston Mason, Jhon R. Cockcroft. (2006) Targeting Nitric Oxide With Drug Therapy. The Journal of Clinical Hypertension 8, 40-52
CrossRef247
Wilbert S. Aronow. (2006) Treatment of heart failure with decreased left ventricular ejection fraction. Comprehensive Therapy 32:4, 218-225
CrossRef248
Pamela Sankar. (2006) Hasty generalisation and exaggerated certainties: reporting genetic findings in health disparities research. New Genetics and Society 25:3, 249-264
CrossRef249
Leopoldo Raij. (2006) Nitric Oxide in the Pathogenesis of Cardiac Disease. The Journal of Clinical Hypertension 8, 30-39
CrossRef250
Melvin R. Echols, G. Michael Felker, Kevin L. Thomas, Karen S. Pieper, Jyotsna Garg, Michael S. Cuffe, Mihai Gheorghiade, Robert M. Califf, Christopher M. O'Connor. (2006) Racial Differences in the Characteristics of Patients Admitted for Acute Decompensated Heart Failure and Their Relation to Outcomes: Results From the OPTIME-CHF Trial. Journal of Cardiac Failure 12:9, 684-688
CrossRef251
Stacie E. Geller, Marci Goldstein Adams, Molly Carnes. (2006) Adherence to Federal Guidelines for Reporting of Sex and Race/Ethnicity in Clinical Trials. Journal of Women's Health 15:10, 1123-1131
CrossRef252
Amalia M Issa, L Todd Weiss, Waqas Tufail, Kathryn A Phillips, Stephanie L Van Bebber. (2006) Innovation in personalized medicine: BiDil ® as a case study for integrating clinical and policy developments. Personalized Medicine 3:4, 421-427
CrossRef253
Jonathan Kahn. (2006) Patenting race. Nature Biotechnology 24:11, 1349-1351
CrossRef254
A. M. Kilbourne, G. Switzer, K. Hyman, M. Crowley-Matoka, M. J. Fine. (2006) Advancing Health Disparities Research Within the Health Care System: A Conceptual Framework. American Journal of Public Health 96:12, 2113-2121
CrossRef255
S. A. Ibrahim, R. A. Stone, D. S. Obrosky, J. Sartorius, M. J. Fine, D. Aujesky. (2006) Racial Differences in 30-Day Mortality for Pulmonary Embolism. American Journal of Public Health 96:12, 2161-2164
CrossRef256
Mark P. Donahue, Douglas A. Marchuk, Howard A. Rockman. (2006) Redefining Heart Failure. Journal of the American College of Cardiology 48:7, 1289-1298
CrossRef257
Erik Tingberg, Anders Roijer, Ulf Thilen, Hans ??hlin. (2006) Neurohumoral Changes in Patients With Left Ventricular Dysfunction Following Acute Myocardial Infarction and the Effect of Nitrate Therapy: A Randomized, Double-Blind, Placebo-Controlled Long-Term Study. Journal of Cardiovascular Pharmacology 48:4, 166-172
CrossRef258
Jonathan Kahn. (2006) Race, Pharmacogenomics, and Marketing: Putting BiDil in Context. The American Journal of Bioethics 6:5, W1-W5
CrossRef259
Richard M. Weinshilboum, Liewei Wang. (2006) Pharmacogenetics and Pharmacogenomics: Development, Science, and Translation. Annual Review of Genomics and Human Genetics 7:1, 223-245
CrossRef260
Dennis M. McNamara, S. William Tam, Michael L. Sabolinski, Page Tobelmann, Karen Janosko, Anne L. Taylor, Jay N. Cohn, Arthur M. Feldman, Manuel Worcel. (2006) Aldosterone Synthase Promoter Polymorphism Predicts Outcome in African Americans With Heart Failure. Journal of the American College of Cardiology 48:6, 1277-1282
CrossRef261
Erik Lillquist, Charles A. Sullivan. (2006) Legal Regulation of the Use of Race in Medical Research. The Journal of Law, Medicine <html_ent glyph="@amp;" ascii="&"/> Ethics 34:3, 535-551
CrossRef262
Michael W. Rich. (2006) Heart Failure in Older Adults. Medical Clinics of North America 90:5, 863-885
CrossRef263
Frank C. Chen, Ozgur Ogut, Albert Y. Rhee, Brian D. Hoit, Frank V. Brozovich. (2006) Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation. Journal of Molecular and Cellular Cardiology 41:3, 488-495
CrossRef264
Udho Thadani, Tiffany Rodgers. (2006) Side effects of using nitrates to treat angina. Expert Opinion on Drug Safety 5:5, 667-674
CrossRef265
Leanne Groban, John Butterworth. (2006) Perioperative Management of Chronic Heart Failure. Anesthesia & Analgesia 103:3, 557-575
CrossRef266
Jay N. Cohn. (2006) The Use of Race and Ethnicity in Medicine: Lessons from the African-American Heart Failure Trial. The Journal of Law, Medicine <html_ent glyph="@amp;" ascii="&"/> Ethics 34:3, 552-554
CrossRef267
RL Bowen, J Stebbing, LJ Jones. (2006) A review of the ethnic differences in breast cancer. Pharmacogenomics 7:6, 935-942
CrossRef268
George Ellison. (2006) Medicine in black and white: BiDilR: race and the limits of evidence-based medicine. Significance 3:3, 118-121
CrossRef269
Jay N. Cohn. (2006) Efficacy and Safety in Clinical Trials in Cardiovascular Disease. Journal of the American College of Cardiology 48:3, 430-433
CrossRef270
Susan Xiuqing Zhao, Lani Mei Lee, Bruce D Nearing, Veronica O Busso, Kevin F Kwaku, Richard L Verrier. (2006) Suppression of Calcium-Induced Repolarization Heterogeneity as a Mechanism of Nitroglycerin??s Antiarrhythmic Action. Journal of Cardiovascular Pharmacology 48:2, 22-29
CrossRef271
Christopher B. Granger, John J.V. McMurray. (2006) Using Measures of Disease Progression to Determine Therapeutic Effect. Journal of the American College of Cardiology 48:3, 434-437
CrossRef272
Daniel G. Krauser, Annabel A. Chen, Roderick Tung, Saif Anwaruddin, Aaron L. Baggish, James L. Januzzi. (2006) Neither Race nor Gender Influences the Usefulness of Amino-Terminal Pro-Brain Natriuretic Peptide Testing in Dyspneic Subjects: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Substudy. Journal of Cardiac Failure 12:6, 452-457
CrossRef273
P. Bauer, J. Einfalt. (2006) Application of Adaptive Designs – a Review. Biometrical Journal 48:4, 493-506
CrossRef274
Robert Weiss. (2006) Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation. Vascular Health and Risk Management 2:3, 303-308
CrossRef275
Josef Stehlik, Matthew A Movsesian. (2006) Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure. Expert Opinion on Investigational Drugs 15:7, 733-742
CrossRef276
Michael A. Crouch. (2006) Pharmacotherapy Implications of Revised Chronic Heart Failure Guidelines. The Consultant Pharmacist 21:7, 576-582
CrossRef277
Albert Yuh-Jer Shen, Somjot S Brar, Steven S Khan, Dean A Kujubu. (2006) Association of race, heart failure and chronic kidney disease. Future Cardiology 2:4, 441-454
CrossRef278
María G. Crespo Leiro, María J. Paniagua Martín. (2006) Insuficiencia cardiaca. ¿Son diferentes las mujeres?. Revista Española de Cardiología 59:7, 725-735
CrossRef279
Belinda Birnbaum, Gurdip S. Sidhu, Robert L. Smith, Michael H. Pillinger, Clement E. Tagoe. (2006) Fulminating hydralazine-induced lupus pneumonitis. Arthritis & Rheumatism 55:3, 501-506
CrossRef280
Lee A. Biblo, Johan Aasbo. (2006) To catch a moving target. Heart Rhythm 3:6, 638-639
CrossRef281
Rachele Adorisio, Leonardo De Luca, Joseph Rossi, Mihai Gheorghiade. (2006) Pharmacological treatment of chronic heart failure. Heart Failure Reviews 11:2, 109-123
CrossRef282
Eric C. Stecker, Megan Sono, Erin Wallace, Karen Gunson, Jonathan Jui, Sumeet S. Chugh. (2006) Allelic variants of SCN5A and risk of sudden cardiac arrest in patients with coronary artery disease. Heart Rhythm 3:6, 697-700
CrossRef283
Judy W.M. Cheng. (2006) A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. Clinical Therapeutics 28:5, 666-678
CrossRef284
Kevin A. Courville, Hector O. Ventura. (2006) Hypertension and heart failure: Diagnosis and management. Current Hypertension Reports 8:3, 185-190
CrossRef285
Jay N. Cohn, Peter E. Carson, Christopher O'Connor, Cristina Opasich, Ileana L. Piña, Marino Scherillo, Gianfranco Sinagra, Lynne Warner-Stevenson, Felix E. Tristani, Alberto Volpi. (2006) Prognosis and Mechanism of Death in Treated Heart Failure: Data From the Placebo Arm of Val-HeFT. Congestive Heart Failure 12:3, 127-131
CrossRef286
Jeff Whittle, Nancy R. Kressin, Eric D. Peterson, Michelle B. Orner, Mark Glickman, Marco Mazzella, Laura A. Petersen. (2006) Racial Differences in Prevalence of Coronary Obstructions Among Men With Positive Nuclear Imaging Studies. Journal of the American College of Cardiology 47:10, 2034-2041
CrossRef287
Markus Flesch, Erland Erdmann. (2006) The problem of polypharmacy in heart failure. Current Cardiology Reports 8:3, 217-225
CrossRef288
Wilbert S. Aronow. (2006) Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure. Cardiology in Review 14:3, 108-124
CrossRef289
Peter Franks, Peter Muennig, Erica Lubetkin, Haomiao Jia. (2006) The burden of disease associated with being African-American in the United States and the contribution of socio-economic status. Social Science & Medicine 62:10, 2469-2478
CrossRef290
Roberto M Saraiva, Joshua M Hare. (2006) Nitric oxide signaling in the cardiovascular system: implications for heart failure. Current Opinion in Cardiology 21:3, 221-228
CrossRef291
Gastone Sabbadini, Marco Metra, Andrea Di Lenarda, Savina Nodari, Gianfranco Sinagra, Livio Dei Cas. (2006) Managing heart failure in the very old. Aging Health 2:2, 253-275
CrossRef292
Lynne Warner Stevenson, Eldrin Lewis. (2006) Mapping the Journey
Editorials published in the Journal of American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 47:8, 1612-1614
CrossRef293
Srinivas Iyengar, William T. Abraham. (2006) Diuretic resistance in heart failure. Current Heart Failure Reports 3:1, 41-45
CrossRef294
M. Böhm, N. Werner, M. Kindermann. (2006) Stand der medikamentösen Therapie bei chronischer Herzinsuffizienz. Clinical Research in Cardiology 95:S4, 36-56
CrossRef295
Roger N. Lancaster. (2006) SEX, SCIENCE, AND PSEUDOSCIENCE IN THE PUBLIC SPHERE. Identities 13:1, 101-138
CrossRef296
Elizabeth A. Stewart, Cynthia C. Morton. (2006) The Genetics of Uterine Leiomyomata. Obstetrics & Gynecology 107:4, 917-921
CrossRef297
David W. Markham, G. Michael Felker. 2006. Vasodilators in the Management of Heart Failure. , 99-112.
CrossRef298
Lynne Warner Stevenson. 2006. Selecting Patients for Durable Support with Ventricular Assist Devices. , 419-432.
CrossRef299
Aruna D Pradhan, Michael M Givertz, Kenneth L Baughman. 2006. Heart Failure and Obesity: The Risk of Development and the Treatment of Heart Failure in Obese Patients. , 403-428.
CrossRef300
Larisa H Cavallari. (2006) Pharmacogenomics in heart failure: individualizing therapy based on genotype. Future Cardiology 2:2, 129-131
CrossRef301
Eldrin F. Lewis, Carol M. Flavell. 2006. Prognosis Assessment and End of Life Issues. , 531-546.
CrossRef302
Katrin Weigmann. (2006) Racial medicine: here to stay?. EMBO reports 7:3, 246-249
CrossRef303
Michael M. Givertz. 2006. Diet, Metabolic Syndrome, and Obesity. , 37-58.
CrossRef304
Keith C. Ferdinand. (2006) The Isosorbide-Hydralazine Story: Is There a Case for Race-Based Cardiovascular Medicine?. The Journal of Clinical Hypertension 8:3, 156-158
CrossRef305
Glen E. Cooke. (2006) Pharmacogenetics of multigenic disease: Heart disease as an example. Vascular Pharmacology 44:2, 66-74
CrossRef306
Heart Failure Society of America. (2006) Section 7: Heart Failure in Patients With Left Ventricular Systolic Dysfunction. Journal of Cardiac Failure 12:1, e38-e57
CrossRef307
John A Fossella. (2006) Genetic structure in human populations: implications for the personalized medicine value chain. Personalized Medicine 3:1, 1-7
CrossRef308
Barry M. Massie, Thomas Force. (2006) The Year in Heart Failure 2005. Journal of Cardiac Failure 12:1, 1-9
CrossRef309
Heart Failure Society of America. (2006) Section 15: Management of Heart Failure in Special Populations. Journal of Cardiac Failure 12:1, e115-e119
CrossRef310
B S Shastry. (2006) Pharmacogenetics and the concept of individualized medicine. The Pharmacogenomics Journal 6:1, 16-21
CrossRef311
Shannon W. Finks, A Lloyd Finks, Timothy H. Self. (2006) Hydralazine-induced Lupus: Maintaining Vigilance with Increased Use in Patients with Heart Failure. Southern Medical Journal 99:1, 18-22
CrossRef312
2006. Nitrates, organic. , 2529-2537.
CrossRef313
Gordon S. Stokes. (2006) Nitrates as adjunct hypertensive treatment. Current Hypertension Reports 8:1, 60-68
CrossRef314
J. Malcolm O. Arnold, Peter Liu, Catherine Demers, Paul Dorian, Nadia Giannetti, Haissam Haddad, George A. Heckman, Jonathan G. Howlett, Andrew Ignaszewski, David E. Johnstone, Philip Jong, Robert S. McKelvie, Gordon W. Moe, John D. Parker, Vivek Rao, Heather J. Ross, Errol J. Sequeira, Anna M. Svendsen, Koon Teo, Ross T. Tsuyuki, Michel White. (2006) Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management. Canadian Journal of Cardiology 22:1, 23-45
CrossRef315
Simon Frantz. (2006) Pharma's year of trouble and strife. Nature Reviews Drug Discovery 5:1, 7-9
CrossRef316
Manuel F. Jiménez Navarro, Javier Díez Martínez, Juan F. Delgado Jiménez, María G. Crespo Leiro. (2006) La insuficiencia cardíaca en el año 2005. Revista Española de Cardiología 59, 55-65
CrossRef317
Wilbert S. Aronow. (2006) Treatment of Systolic and Diastolic Heart Failure in the Elderly. Journal of the American Medical Directors Association 7:1, 29-36
CrossRef318
David S. Jones, Roy H. Perlis. (2006) Pharmacogenetics, Race, and Psychiatry: Prospects and Challenges. Harvard Review of Psychiatry 14:2, 92-108
CrossRef319
Sonal Singh. (2006) Hydralazine-induced Lupus. Southern Medical Journal 99:1, 6-7
CrossRef320
Ulf Landmesser, Helmut Drexler. (2005) Chronic heart failure: an overview of conventional treatment versus novel approaches. Nature Clinical Practice Cardiovascular Medicine 2:12, 628-638
CrossRef321
Lorraine Frazier, Rolanda L. Johnson, Elizabeth Sparks. (2005) Genomics and Cardiovascular Disease. Journal of Nursing Scholarship 37:4, 315-321
CrossRef322
Andreas Daiber, Matthias Oelze, Meike Coldewey, K. Kaiser, C. Huth, S. Schildknecht, M. Bachschmid, Y. Nazirisadeh, V. Ullrich, A. Mülsch, T. Münzel, N. Tsilimingas. (2005) Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochemical and Biophysical Research Communications 338:4, 1865-1874
CrossRef323
W. S. Aronow. (2005) Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60:12, 1597-1605
CrossRef324
W.H. Wilson Tang, Gary S. Francis. (2005) The Year in Heart Failure. Journal of the American College of Cardiology 46:11, 2125-2133
CrossRef325
Ruggiero Mango, Lucia Vecchione, Barbara Raso, Paola Borgiani, Ercole Brunetti, Jawahar L Mehta, Renato Lauro, Francesco Romeo, Giuseppe Novelli. (2005) Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy. Expert Opinion on Pharmacotherapy 6:15, 2565-2576
CrossRef326
M. J. Fine, S. A. Ibrahim, S. B. Thomas. (2005) The Role of Race and Genetics in Health Disparities Research. American Journal of Public Health 95:12, 2125-2128
CrossRef327
PATRICIA O'MALLEY. (2005) Ethnic Pharmacology. Clinical Nurse Specialist 19:6, 291-293
CrossRef328
Keith C Ferdinand. (2005) Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety. Expert Review of Cardiovascular Therapy 3:6, 993-1001
CrossRef329
Michelle M Kittleson, Joshua M Hare. (2005) Molecular signature analysis: the potential of gene-expression analysis in cardiomyopathy. Future Cardiology 1:6, 793-808
CrossRef330
Tadeusz Malinski. (2005) Understanding Nitric Oxide Physiology in the Heart: A Nanomedical Approach. The American Journal of Cardiology 96:7, 13-24
CrossRef331
Andreas Daiber, Alexander Mülsch, Ulrich Hink, Hanke Mollnau, Ascan Warnholtz, Matthias Oelze, Thomas Münzel. (2005) The Oxidative Stress Concept of Nitrate Tolerance and the Antioxidant Properties of Hydralazine. The American Journal of Cardiology 96:7, 25-36
CrossRef332
Clyde W. Yancy. (2005) Heart Failure in African Americans. The American Journal of Cardiology 96:7, 3-12
CrossRef333
JOHN J V MCMURRAY. (2005) Chronic kidney disease in patients with cardiac disease: A review of evidence-based treatment. Kidney International 68:4, 1419-1426
CrossRef334
M.G. Crespo Leiro, R. Marzoa Rivas, M.J. Paniagua Martín, A. Castro Beiras. (2005) Miocardiopatías: concepto, clasificación. Miocardiopatía dilatada idiopática. Medicine - Programa de Formación Médica Continuada Acreditado 9:42, 2765-2774
CrossRef335
Uri Elkayam, Fahed Bitar. (2005) Effects of Nitrates and Hydralazine in Heart Failure: Clinical Evidence Before the African American Heart Failure Trial. The American Journal of Cardiology 96:7, 37-43
CrossRef336
Srinivas Murali, Marie R. Baldisseri. (2005) Peripartum cardiomyopathy. Critical Care Medicine 33:Supplement, S340-S346
CrossRef337
Anne L. Taylor. (2005) The African American Heart Failure Trial: A Clinical Trial Update. The American Journal of Cardiology 96:7, 44-48
CrossRef338
James D. Neaton, Gerry Gray, Bram D. Zuckerman, Marvin A. Konstam. (2005) Key Issues in End Point Selection for Heart Failure Trials: Composite End Points. Journal of Cardiac Failure 11:8, 567-575
CrossRef339
John V Terrovitis, Maria I Anastasiou-Nana, John N Nanas. (2005) Out-patient management of chronic heart failure. Expert Opinion on Pharmacotherapy 6:11, 1857-1881
CrossRef340
Ezra A. Amsterdam. (2005) Revised American College of Cardiology/American Heart Association Guidelines for the Management of Heart Failure. Preventive Cardiology 8:4, 254-256
CrossRef341
Sharon Ann Hunt. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Journal of the American College of Cardiology 46:6, e1-e82
CrossRef342
Sharon Ann Hunt, William T. Abraham, Marshall H. Chin, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Mariell Jessup, Marvin A. Konstam, Donna M. Mancini, Keith Michl, John A. Oates, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article. Journal of the American College of Cardiology 46:6, 1116-1143
CrossRef343
(2005) Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Versión resumida (actualización 2005). Revista Española de Cardiología 58:9, 1062-1092
CrossRef344
Michael A. Crouch. (2005) Chronic Heart Failure: Developments and Perspectives. The Consultant Pharmacist 20:9, 751-765
CrossRef345
Crystal A. Gadegbeku, Janice P. Lea, Kenneth A. Jamerson. (2005) Update on Disparities in the Pathophysiology and Management of Hypertension: Focus on African Americans. Medical Clinics of North America 89:5, 921-933
CrossRef346
Emily Singer. (2005) Race-based heart drug might stall search for better markers. Nature Medicine 11:8, 812-812
CrossRef347
Sandeep A. Kamath, Clyde W. Yancy. (2005) Treatment of the african-american patient with congestive heart failure. Current Treatment Options in Cardiovascular Medicine 7:4, 307-315
CrossRef348
Michael W. Smith, Stephen J. O'Brien. (2005) Mapping by admixture linkage disequilibrium: advances, limitations and guidelines. Nature Reviews Genetics 6:8, 623-632
CrossRef349
U. C. Hoppe, M. Böhm, R. Dietz, P. Hanrath, H. K. Kroemer, A. Osterspey, A. A. Schmaltz, E. Erdmann. (2005) Leitlinien zur Therapie der chronischen Herzinsuffizienz. Zeitschrift für Kardiologie 94:8, 488-509
CrossRef350
Addison A. Taylor, James L. Pool. (2005) Clinical Pharmacology of Antihypertensive Therapy. Seminars in Nephrology 25:4, 215-226
CrossRef351
Jonathan Kahn. (2005) Misreading race and genomics after BiDil. Nature Genetics 37:7, 655-656
CrossRef352
Thomas W. Wallace, Mark H. Drazner. (2005) The impact of race on response to RAAS inhibition. Current Heart Failure Reports 2:2, 72-77
CrossRef353
Osama A. Ibrahim, Mark E. Dunlap. (2005) Combination pharmacologic therapies for heart failure: What next after angiotensin-converting enzyme inhibitors and beta-blockers?. Current Heart Failure Reports 2:2, 89-93
CrossRef354
Mary Norine Walsh. (2005) Advanced heart failure and transplantation in women. Current Cardiology Reports 7:3, 184-189
CrossRef355
Randall C. Starling. (2005) Inducible Nitric Oxide Synthase in Severe Human Heart Failure
CrossRef356
G Michael Felker. (2005) The African–American heart failure trial: a new look at old drugs. Future Cardiology 1:3, 311-313
CrossRef357
Theo E. Meyer. (2005) Clinical trials report. Current Cardiology Reports 7:3, 193-195
CrossRef358
John JV McMurray, Marc A Pfeffer. (2005) Heart failure. The Lancet 365:9474, 1877-1889
CrossRef359
(2005) Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. New England Journal of Medicine 352:10, 1041-1043
Full Text360
Abdallah S. Daar, Peter A. Singer. (2005) Opinion: Pharmacogenetics and geographical ancestry: implications for drug development and global health. Nature Reviews Genetics 6:3, 241-246
CrossRef361
Eyal Herzog, Cathleen Varley, Marrick Kukin. (2005) Pathway for the Management of Acute Heart Failure. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 4:1, 37-42
CrossRef362
Frank J. Giordano. (2005) Oxygen, oxidative stress, hypoxia, and heart failure. Journal of Clinical Investigation 115:3, 500-508
CrossRef363
Richard I. Shader. (2005) Looking Back and Looking Forward. Journal of Clinical Psychopharmacology 25:1, 1-2
CrossRef364
Eric J Topol. (2005) Cholesterol, racial variation and targeted medicines. Nature Medicine 11:2, 122-123
CrossRef365
Stephan von Haehling, Stefan D Anker. (2005) Future prospects of anticytokine therapy in chronic heart failure. Expert Opinion on Investigational Drugs 14:2, 163-176
CrossRef366
Barry M. Massie. (2005) The year in heart failure: 2004. Journal of Cardiac Failure 11:1, 1-6
CrossRef367
Ian Hacking. (2005) Why race still matters. Daedalus 134:1, 102-116
CrossRef368
(2005) A-HeFT trial: positive results. Nature Clinical Practice Cardiovascular Medicine 2:1, 4-5
CrossRef369
Javier Bermejo, Javier Segovia, Fernando Alfonso. (2005) Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (New Orleans, Estados Unidos, 7-10 de noviembre de 2004). Revista Española de Cardiología 58:1, 54-64
CrossRef370
Gail McBride. (2005) The Coming of Age of Multicultural Medicine. PLoS Medicine 2:3, e62
CrossRef371
Jean-Paul Schmid, Verena Schroeder. (2005) Nicorandil – Review of Pharmacological Properties and Clinical Applications. Heart Drug 5:4, 220-229
CrossRef372
(2004) News in Brief. Nature Reviews Drug Discovery 3:12, 988-988
CrossRef373
Damaris Christensen. (2004) Scientists divided on relevance of race in medical research. Nature Medicine 10:12, 1266-1266
CrossRef374
Hare, Joshua M., . (2004) Nitroso–Redox Balance in the Cardiovascular System. New England Journal of Medicine 351:20, 2112-2114
Full Text375
Bloche, M. Gregg, . (2004) Race-Based Therapeutics. New England Journal of Medicine 351:20, 2035-2037
Full Text
- Letters
